## Jonathan I Epstein

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8061960/publications.pdf

Version: 2024-02-01

592 papers

53,121 citations

112 h-index 205 g-index

600 all docs

600 docs citations

600 times ranked

20537 citing authors

#	Article	IF	CITATIONS
1	Intraductal Adenocarcinoma of the Prostate With Cribriform or Papillary Ductal Morphology. American Journal of Surgical Pathology, 2022, 46, 233-240.	3.7	6
2	Is Grade Group 1 (Gleason score 3 + 3 = 6) adenocarcinoma of the prostate really cancer?. Current Opinion in Urology, 2022, 32, 91-95.	1.8	11
3	Pathological characterization and clinical outcome of penile intraepithelial neoplasia variants: a North American series. Modern Pathology, 2022, , .	5 <b>.</b> 5	3
4	Molecular Characterization of Metanephric Adenoma, Epithelial Wilms Tumor, and Overlap Lesions: An Integrated Whole-exome and Transcriptome Sequencing Analysis. Applied Immunohistochemistry and Molecular Morphology, 2022, 30, 257-263.	1.2	2
5	Intraductal Carcinoma of the Prostate. American Journal of Surgical Pathology, 2022, Publish Ahead of Print, .	3.7	1
6	Verrucous Squamous Hyperplasia of the Urinary Bladder. Archives of Pathology and Laboratory Medicine, 2022, , .	2.5	0
7	Renaming Gleason Score 6 Prostate to Noncancer: A Flawed Idea Scientifically and for Patient Care. Journal of Clinical Oncology, 2022, 40, 3106-3109.	1.6	16
8	The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer. Archives of Pathology and Laboratory Medicine, 2021, 145, 461-493.	2.5	143
9	PINâ€like ductal carcinoma of the prostate has frequent activating RAS/RAF mutations. Histopathology, 2021, 78, 327-333.	2.9	9
10	Head to head: should the intraductal component of invasive prostate cancer be graded?. Histopathology, 2021, 78, 231-239.	2.9	26
11	Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary Pathology Society clinician survey. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 295.e1-295.e8.	1.6	6
12	Intraductal carcinoma of the prostate does not always represent invasive highâ€grade carcinoma extending into ducts. Histopathology, 2021, 78, 345-346.	2.9	1
13	Well-differentiated neuroendocrine tumors of the lower urinary tract: biologic behavior of a rare entity. Human Pathology, 2021, 109, 53-58.	2.0	5
14	Genomic and phenotypic heterogeneity in prostate cancer. Nature Reviews Urology, 2021, 18, 79-92.	3.8	215
15	Nested Variant of Urothelial Carcinoma Is a Luminal Bladder Tumor With Distinct Coexpression of the Basal Marker Cytokeratin 5/6. American Journal of Clinical Pathology, 2021, 155, 588-596.	0.7	10
16	Adverse histology, homozygous loss of CDKN2A/B, and complex genomic alterations in locally advanced/metastatic renal mucinous tubular and spindle cell carcinoma. Modern Pathology, 2021, 34, 445-456.	5.5	15
17	A Comparison of Genitourinary Pathology Society (GUPS) and International Society of Urological Pathology (ISUP) Prostate Cancer Grading Guidelines. American Journal of Surgical Pathology, 2021, Publish Ahead of Print, 1005-1007.	3.7	3
18	Advances in the selection of patients with prostate cancer for active surveillance. Nature Reviews Urology, 2021, 18, 197-208.	3.8	21

#	Article	IF	Citations
19	Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. Modern Pathology, 2021, 34, 1167-1184.	<b>5.</b> 5	118
20	New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. Modern Pathology, 2021, 34, 1392-1424.	5.5	138
21	Transperineal Prostate Biopsy Improves the Detection of Clinically Significant Prostate Cancer among Men on Active Surveillance. Journal of Urology, 2021, 205, 1069-1074.	0.4	21
22	Plasma cell neoplasms of the bladder: a series of 9 cases. Human Pathology, 2021, 111, 52-58.	2.0	0
23	Urothelial Differences in the Exstrophy-Epispadias Complex: Potential Implications for Management. Journal of Urology, 2021, 205, 1460-1465.	0.4	4
24	The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers. Advances in Anatomic Pathology, 2021, 28, 196-208.	4.3	20
25	Very lowâ€risk versus lowâ€risk prostate cancer: A distinction worth keeping. Prostate, 2021, 81, 923-925.	2.3	0
26	Noninvasive low-grade papillary urothelial carcinoma with degenerative nuclear atypia: a grading pitfall. Human Pathology, 2021, 113, 1-8.	2.0	1
27	Reexamining the molecular findings in specialized stromal tumors of the prostate. Modern Pathology, 2021, 34, 2080-2081.	5.5	1
28	Clear Cell Adenocarcinoma in Men. American Journal of Surgical Pathology, 2021, 45, 270-276.	3.7	11
29	Contemporary Characterization and Recategorization of Adult Unclassified Renal Cell Carcinoma. American Journal of Surgical Pathology, 2021, 45, 450-462.	3.7	7
30	Multiphoton Microscopy for Identifying Collagen Signatures Associated with Biochemical Recurrence in Prostate Cancer Patients. Journal of Personalized Medicine, 2021, 11, 1061.	2.5	7
31	Diagnosis of "cribriform" prostatic adenocarcinoma: an interobserver reproducibility study among urologic pathologists with recommendations. American Journal of Cancer Research, 2021, 11, 3990-4001.	1.4	4
32	SATB2 protein expression by immunohistochemistry is a sensitive and specific marker of appendiceal and rectosigmoid well differentiated neuroendocrine tumours. Histopathology, 2020, 76, 550-559.	2.9	16
33	Is There Enough Support for a New Prostate Grading System Factoring in Intraductal Carcinoma and Cribriform Cancer?. European Urology, 2020, 77, 199-200.	1.9	4
34	RNA Expression Profiling of Lymphoepithelioma-Like Carcinoma of the Bladder Reveals a Basal-Like Molecular Subtype. American Journal of Pathology, 2020, 190, 134-144.	3.8	13
35	Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort. European Urology, 2020, 77, 675-682.	1.9	137
36	Gleason score 5 + 3 = 8 (grade group 4) prostate cancer—a rare occurrence with contemporary gradi Human Pathology, 2020, 97, 40-51.	ng. 2.0	14

#	Article	IF	CITATIONS
37	Reporting Practices and Resource Utilization in the Era of Intraductal Carcinoma of the Prostate. American Journal of Surgical Pathology, 2020, 44, 673-680.	3.7	31
38	Computer Extracted Features from Initial H& E Tissue Biopsies Predict Disease Progression for Prostate Cancer Patients on Active Surveillance. Cancers, 2020, 12, 2708.	3.7	17
39	Neuroendocrine differentiation in usualâ€type prostatic adenocarcinoma: Molecular characterization and clinical significance. Prostate, 2020, 80, 1012-1023.	2.3	22
40	Gastrointestinal Malakoplakia. American Journal of Surgical Pathology, 2020, 44, 1251-1258.	3.7	12
41	Prostate Health Index and multiparametric magnetic resonance imaging to predict prostate cancer grade reclassification in active surveillance. BJU International, 2020, 126, 373-378.	2.5	25
42	Fungal prostatitis due to endemic mycoses and Cryptococcus : A multicenter case series. Prostate, 2020, 80, 1006-1011.	2.3	4
43	Evaluation of Apparent Diffusion Coefficient as a Predictor of Grade Reclassification in Men on Active Surveillance for Prostate Cancer. Urology, 2020, 138, 84-90.	1.0	2
44	Downgrading of grade group 2 intermediateâ€risk prostate cancer from biopsy to radical prostatectomy: Comparison of outcomes and predictors to identify potential candidates for active surveillance. Cancer, 2020, 126, 1632-1639.	4.1	8
45	Prospective evaluation of fexapotide triflutate injection treatment of Grade Group 1 prostate cancer: 4-year results. World Journal of Urology, 2020, 38, 3101-3111.	2.2	2
46	Gleason pattern 4 with cribriform morphology on biopsy is associated with adverse clinicopathological findings in a prospective radical prostatectomy cohort. Human Pathology, 2020, 98, 74-80.	2.0	21
47	Utility of multiparametric magnetic resonance imaging in the risk stratification of men with Grade Group 1 prostate cancer on active surveillance. BJU International, 2020, 125, 861-866.	2.5	19
48	Telomere lengths differ significantly between small-cell neuroendocrine prostate carcinoma and adenocarcinoma of the prostate. Human Pathology, 2020, 101, 70-79.	2.0	5
49	Significance of Paneth cell–like differentiation in prostatic adenocarcinoma: a retrospective cohort study of 80 cases. Human Pathology, 2020, 102, 7-12.	2.0	6
50	How Are Gleason Scores Categorized in the Current Literature: An Analysis and Comparison of Articles Published in 2016–2017. European Urology, 2019, 75, 25-31.	1.9	8
51	PAX8 positivity in nested variant of urothelial carcinoma: a potential diagnostic pitfall. Human Pathology, 2019, 94, 11-15.	2.0	17
52	Plasmacytoid acinar adenocarcinoma of the prostate: a newly described variant of prostate cancer. Human Pathology, 2019, 94, 86-91.	2.0	5
53	Primary adenocarcinoma of the bladder lacks mismatch repair deficiency and demonstrates PD-L1 expression in tumor-infiltrating immune cells, with implications in both diagnosis and therapeutics. Human Pathology, 2019, 94, 58-63.	2.0	6
54	Intraductal carcinoma of the prostate in the absence of highâ€grade invasive carcinoma represents a molecularly distinct type of ⟨i⟩in situ⟨/i⟩ carcinoma enriched with oncogenic driver mutations. Journal of Pathology, 2019, 249, 79-89.	4.5	44

#	Article	lF	Citations
55	Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene Mutations. JCO Precision Oncology, 2019, 3, 1-9.	3.0	47
56	Defining clinically significant prostate cancer on the basis of pathological findings. Histopathology, 2019, 74, 135-145.	2.9	114
57	DNA damage repair alterations are frequent in prostatic adenocarcinomas with focal pleomorphic giantâ€eell features. Histopathology, 2019, 74, 836-843.	2.9	15
58	Mimickers of urothelial neoplasia. Annals of Diagnostic Pathology, 2019, 38, 11-19.	1.3	16
59	Editorial Comment. Journal of Urology, 2019, 201, 540-540.	0.4	0
60	Intraoperative Consultation and Macroscopic Handling. American Journal of Surgical Pathology, 2018, 42, e33-e43.	3.7	16
61	An expanded immunohistochemical profile of osteoclast-rich undifferentiated carcinoma of the urinary tract. Modern Pathology, 2018, 31, 984-988.	5 <b>.</b> 5	12
62	Incidence of Extraprostatic Extension at Radical Prostatectomy with Pure Gleason Score 3 + 3 = 6 (Grade Group 1) Cancer: Implications for Whether Gleason Score 6 Prostate Cancer Should be Renamed "Not Cancer" and for Selection Criteria for Active Surveillance. Journal of Urology, 2018, 199, 1482-1487.	0.4	27
63	Whole-exome sequencing demonstrates recurrent somatic copy number alterations and sporadic mutations in specialized stromal tumors of the prostate. Human Pathology, 2018, 76, 9-16.	2.0	4
64	Reappraisal of Morphologic Differences Between Renal Medullary Carcinoma, Collecting Duct Carcinoma, and Fumarate Hydratase–deficient Renal Cell Carcinoma. American Journal of Surgical Pathology, 2018, 42, 279-292.	3.7	101
65	Prostate cancer grading: a decade after the 2005 modified system. Modern Pathology, 2018, 31, 47-63.	5.5	83
66	Adverse Pathologic Findings for Men Electing Immediate Radical Prostatectomy. JAMA Oncology, 2018, 4, 89.	7.1	52
67	Managing high-grade prostatic intraepithelial neoplasia (HGPIN) and atypical glands on prostate biopsy. Nature Reviews Urology, 2018, 15, 55-66.	3.8	18
68	Reâ€evaluation of 33 â€~unclassified' eosinophilic renal cell carcinomas in young patients. Histopathology, 2018, 72, 588-600.	2.9	92
69	Tumor Volume on Biopsy of Low Risk Prostate Cancer Managed with Active Surveillance. Journal of Urology, 2018, 199, 954-960.	0.4	11
70	The World Health Organisation 2016 classification of penile carcinomas: a review and update from the International Society of Urological Pathology expertâ€driven recommendations. Histopathology, 2018, 72, 893-904.	2.9	52
71	VSTM2A Overexpression Is a Sensitive and Specific Biomarker for Mucinous Tubular and Spindle Cell Carcinoma (MTSCC) of the Kidney. American Journal of Surgical Pathology, 2018, 42, 1571-1584.	3.7	34
72	Eosinophilic Solid and Cystic (ESC) Renal Cell Carcinomas Harbor TSC Mutations. American Journal of Surgical Pathology, 2018, 42, 1166-1181.	3.7	98

#	Article	lF	CITATIONS
73	PIN-like (Ductal) Adenocarcinoma of the Prostate. American Journal of Surgical Pathology, 2018, 42, 1693-1700.	3.7	12
74	Prostatic Adenocarcinoma With Focal Pleomorphic Giant Cell Features. American Journal of Surgical Pathology, 2018, 42, 1286-1296.	3.7	31
75	Granular Cell Tumor of the Bladder: A Report of Six Cases. Urology, 2018, 121, 203.e1-203.e5.	1.0	5
76	ETS2 is a prostate basal cell marker and is highly expressed in prostate cancers aberrantly expressing p63. Prostate, 2018, 78, 896-904.	2.3	13
77	Stratifying Risk for Men With Low-Volume Intermediate-Risk Prostate Cancer—Reply. JAMA Oncology, 2018, 4, 1133.	7.1	0
78	Subtyping the Risk of Intermediate Risk Prostate Cancer for Active Surveillance Based on Adverse Pathology at Radical Prostatectomy. Journal of Urology, 2018, 200, 1068-1074.	0.4	15
79	Challenges in Pathologic Staging of Renal Cell Carcinoma. American Journal of Surgical Pathology, 2018, 42, 1253-1261.	3.7	22
80	Features and Prognostic Significance of Intraductal Carcinoma of the Prostate. European Urology Oncology, 2018, 1, 21-28.	5.4	27
81	Gleason 6 Tumors Should Still Be Labeled as Cancer. Current Clinical Urology, 2018, , 41-52.	0.0	1
82	Genomic characterization of ductal adenocarcinoma of the prostate Journal of Clinical Oncology, 2018, 36, 5030-5030.	1.6	1
83	The Role of Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Biopsy in Active Surveillance. European Urology, 2017, 71, 174-180.	1.9	75
84	Reply to Christian Daniel Fankhauser, Lorelei A. Mucci, and Travis A. Gerke's Letter to the Editor re: Won Sik Ham, Heather J. Chalfin, Zhaoyong Feng, et al. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8–10 Prostate Cancer. Eur Urol 2017;71:907–12. European Urology, 2017, 72, e11-e12.	1.9	1
85	Prognostic value of prostate biopsy grade: forever a product of sampling. BJU International, 2017, 119, 5-7.	2.5	2
86	Pathological Findings in Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion-guided Biopsy: Relation to Prostate Cancer Focal Therapy. Urology, 2017, 105, 18-23.	1.0	11
87	Accuracy of Grading Gleason Score 7 Prostatic Adenocarcinoma on Needle Biopsy: Influence of Percent Pattern 4 and Other Histological Factors. Prostate, 2017, 77, 681-685.	2.3	17
88	Improving the evaluation and diagnosis of clinically significant prostate cancer. Current Opinion in Urology, 2017, 27, 191-197.	1.8	11
89	Pericytic tumors of the kidney—a clinicopathologic analysis of 17 cases. Human Pathology, 2017, 64, 106-117.	2.0	16
90	Contemporary Gleason Grading of Prostatic Carcinoma. American Journal of Surgical Pathology, 2017, 41, e1-e7.	3.7	233

#	Article	IF	CITATIONS
91	Comparison of Biochemical Recurrence-Free Survival after Radical Prostatectomy Triggered by Grade Reclassification during Active Surveillance and in Men Newly Diagnosed with Similar Grade Disease. Journal of Urology, 2017, 198, 608-613.	0.4	6
92	Low-risk Prostate Cancer: Identification, Management, and Outcomes. European Urology, 2017, 72, 238-249.	1.9	55
93	Prostate Cancer Grade Groups Correlate with Prostate-specific Cancer Mortality: SEER Data for Contemporary Graded Specimens. European Urology, 2017, 71, 764-765.	1.9	4
94	In response to â€~a plea for greater standardization' in intraductal carcinoma of the prostate: greater standardization requires greater evidence. Histopathology, 2017, 70, 1011-1013.	2.9	7
95	The effect of limited (tertiary) Gleason pattern 5 on the new prostate cancer grade groups. Human Pathology, 2017, 63, 27-32.	2.0	28
96	Latest Novelties on the World Health Organization Morphological Classifications of Genitourinary Cancers. European Urology Supplements, 2017, 16, 199-209.	0.1	5
97	Sarcomatoid carcinoma associated with small cell carcinoma of the urinary bladder: a series of 28 cases. Human Pathology, 2017, 67, 169-175.	2.0	9
98	Role of SATB2 in distinguishing the site of origin in glandular lesions of the bladder/urinary tract. Human Pathology, 2017, 67, 152-159.	2.0	18
99	Safety and Feasibility of Direct Magnetic Resonance Imaging-guided Transperineal Prostate Biopsy Using a Novel Magnetic Resonance Imaging-safe Robotic Device. Urology, 2017, 109, 216-221.	1.0	13
100	MSH2 Loss in Primary Prostate Cancer. Clinical Cancer Research, 2017, 23, 6863-6874.	7.0	122
101	In Reply. Archives of Pathology and Laboratory Medicine, 2017, 141, 183-184.	2.5	3
102	Central pathology review of radical prostatectomy specimens does make a difference not only with grade. BJU International, 2017, 120, E5-E6.	2.5	0
103	Chromosomal abnormalities of highâ€grade mucinous tubular and spindle cell carcinoma of the kidney. Histopathology, 2017, 71, 719-724.	2.9	20
104	Prognostic significance of extensive necrosis in renal cell carcinoma. Human Pathology, 2017, 66, 108-114.	2.0	16
105	The World Health Organization 2016 classification of testicular nonâ€germ cell tumours: a review and update from the International Society of Urological Pathology Testis Consultation Panel. Histopathology, 2017, 70, 513-521.	2.9	143
106	The World Health Organization 2016 classification of testicular germ cell tumours: a review and update from the International Society of Urological Pathology Testis Consultation Panel. Histopathology, 2017, 70, 335-346.	2.9	165
107	The Impact of Downgrading from Biopsy Gleason 7 to Prostatectomy Gleason 6 on Biochemical Recurrence and Prostate Cancer Specific Mortality. Journal of Urology, 2017, 197, 1060-1067.	0.4	10
108	Significance of Gleason Score 7 With Tertiary Pattern 5 at Radical Prostatectomy. Urology, 2017, 100, 175-179.	1.0	13

#	Article	IF	CITATIONS
109	New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8–10 Prostate Cancer. European Urology, 2017, 71, 907-912.	1.9	44
110	Metastatic potential to regional lymph nodes with Gleason score â‰, including tertiary pattern 5, at radical prostatectomy. BJU International, 2017, 119, 872-878.	2.5	11
111	Pathological analysis of the prostatic anterior fat pad at radical prostatectomy: insights from a prospective series. BJU International, 2017, 119, 444-448.	2.5	13
112	Risk prediction tool for grade reâ€classification in men with favourableâ€risk prostate cancer on active surveillance. BJU International, 2017, 120, 25-31.	2.5	29
113	Nuclear Shape and Architecture in Benign Fields Predict Biochemical Recurrence in Prostate Cancer Patients Following Radical Prostatectomy: Preliminary Findings. European Urology Focus, 2017, 3, 457-466.	3.1	46
114	Prediction of pathological stage based on clinical stage, serum prostateâ€specific antigen, and biopsy Gleason score: Partin Tables in the contemporary era. BJU International, 2017, 119, 676-683.	2.5	86
115	Polypoid urothelial tumor with inverted growth pattern in the renal pelvis: morphologic and molecular characteristics of a unique diagnostic entity. Human Pathology, 2017, 59, 26-33.	2.0	2
116	Advance on curvelet application to prostate cancer tissue image classification., 2017,,.		1
117	Correlation of 99mTc-sestamibi uptake in renal masses with mitochondrial content and multi-drug resistance pump expression. EJNMMI Research, 2017, 7, 80.	2.5	33
118	Understanding PSA and its derivatives in prediction of tumor volume: addressing health disparities in prostate cancer risk stratification. Oncotarget, 2017, 8, 20802-20812.	1.8	11
119	Comparison of biochemical recurrence-free survival after radical prostatectomy among men in active surveillance following grade reclassification and men newly diagnosed with similar grade disease Journal of Clinical Oncology, 2017, 35, 117-117.	1.6	0
120	Comparison of biochemical recurrence free survival after radical prostatectomy triggered by grade reclassification on active surveillance, and men newly diagnosed with similar grade disease Journal of Clinical Oncology, 2017, 35, 5047-5047.	1.6	0
121	Active surveillance of prostate cancer: Current state of practice and utility of multiparametric magnetic resonance imaging. Reviews in Urology, 2017, 19, 77-88.	0.9	8
122	Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, e235-e245.	3.8	26
123	Grading of Prostate Cancer in the 21 <sup>St</sup> Century. Urologia, 2016, 83, 1-3.	0.7	2
124	Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e235-e245.	3.8	16
125	Changes in prostate cancer grading: Including a new patientâ€centric grading system. Prostate, 2016, 76, 427-433.	2.3	36
126	A subset of fat-predominant angiomyolipomas label for MDM2 : a potential diagnostic pitfall. Human Pathology, 2016, 57, 7-12.	2.0	15

#	Article	IF	Citations
127	Carcinoma of the Uterine Cervix Involving the Genitourinary Tract. American Journal of Surgical Pathology, 2016, 40, 27-35.	3.7	28
128	International Society of Urological Pathology (ISUP) Grading of Prostate Cancer: Author's Reply. American Journal of Surgical Pathology, 2016, 40, 862-864.	3.7	9
129	Re: Clinical significance of prospectively assigned gleason tertiary pattern 4 in contemporary Gleason score 3 + 3 = 6 prostate cancer. Prostate, 2016, 76, 1130-1131.	2.3	5
130	Curvelet-based texture classification of critical Gleason patterns of prostate histological images. , $2016, \ldots$		3
131	The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. American Journal of Surgical Pathology, 2016, 40, 244-252.	3.7	2,256
132	Prevalence and distribution of 15 high-risk human papillomavirus types in squamous cell carcinoma of the scrotum. Human Pathology, 2016, 53, 130-136.	2.0	7
133	The utility of STAT6 and ALDH1 expression in the differential diagnosis of solitary fibrous tumor versus prostate-specific stromal neoplasms. Human Pathology, 2016, 54, 184-188.	2.0	31
134	New prostate cancer grade group system correlates with prostate cancer death in addition to biochemical recurrence. British Journal of Cancer, 2016, 114, 1069-1070.	6.4	6
135	Do Black NonHispanic Men Produce Less Prostate Specific Antigen in Benign Prostate Tissue or Cancer Compared to White NonHispanic Men with Gleason Score 6 (Grade Group 1) Prostate Cancer?. Journal of Urology, 2016, 196, 1659-1663.	0.4	9
136	Accuracy of urethral frozen section during radical cystectomy for bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 532.e1-532.e6.	1.6	13
137	Current concepts in the diagnosis and pathobiology of intraepithelial neoplasia: A review by organ system. Ca-A Cancer Journal for Clinicians, 2016, 66, 408-436.	329.8	33
138	Current Gleason score 3Â+Â4Â=Â7: has it lost its significance compared with its historical counterpart?. BJU International, 2016, 117, 853-854.	2.5	0
139	Risk score predicts highâ€grade prostate cancer in DNAâ€methylation positive, histopathologically negative biopsies. Prostate, 2016, 76, 1078-1087.	2.3	74
140	Renal oncocytoma with vascular invasion: a series of 22 cases. Human Pathology, 2016, 58, 1-6.	2.0	38
141	Editorial Comment. Journal of Urology, 2016, 196, 1081-1081.	0.4	1
142	Interobserver Reproducibility of Percent Gleason Pattern 4 in Prostatic Adenocarcinoma on Prostate Biopsies. American Journal of Surgical Pathology, 2016, 40, 1686-1692.	3.7	37
143	Tubulocystic Carcinoma of the Kidney With Poorly Differentiated Foci. American Journal of Surgical Pathology, 2016, 40, 1457-1472.	3.7	112
144	Contemporary Gleason grading and novel Grade Groups in clinical practice. Current Opinion in Urology, 2016, 26, 488-492.	1.8	32

#	Article	IF	Citations
145	Urology journals recommend new prostate cancer grade groups. Nature Reviews Urology, 2016, 13, 374-375.	3.8	5
146	Grading of prostatic adenocarcinoma: current state and prognostic implications. Diagnostic Pathology, 2016, 11, 25.	2.0	201
147	Does the distance between tumor and margin in radical prostatectomy specimens correlate with prognosis: relation to tumor location. Human Pathology, 2016, 56, 11-15.	2.0	7
148	Definition of Insignificant Tumor Volume of Gleason Score 3 + 3 = 6 (Grade Group 1) Prostate Cancer at Radical Prostatectomyâ€"Is it Time to Increase the Threshold?. Journal of Urology, 2016, 196, 1664-1669.	0.4	23
149	Prostate Cancer Grading. American Journal of Surgical Pathology, 2016, 40, 137.	3.7	25
150	Prostate-specific Antigen Mass Densityâ€"A Measure Predicting Prostate Cancer Volume and Accounting for Overweight and Obesity-related Prostate-specific Antigen Hemodilution. Urology, 2016, 90, 141-147.	1.0	11
151	Prostate Cancer Grading: A Decade After the 2005 Modified Gleason Grading System. Archives of Pathology and Laboratory Medicine, 2016, 140, 1140-1152.	2.5	74
152	Diagnostic dilemmas in enlarged and diffusely hemorrhagic adrenal glands. Human Pathology, 2016, 53, 63-72.	2.0	10
153	Differential Diagnosis of Intraductal Lesions of the Prostate. American Journal of Surgical Pathology, 2016, 40, e67-e82.	3.7	31
154	Grading of Prostate Cancer: Past, Present, and Future. Current Urology Reports, 2016, 17, 25.	2.2	32
155	Significance of a minor high-grade component in a low-grade noninvasive papillary urothelial carcinoma of bladder. Human Pathology, 2016, 47, 20-25.	2.0	39
156	Round cell pattern of prostatic stromal tumor of uncertain malignant potential: a subtle newly recognized variant. Human Pathology, 2016, 52, 68-73.	2.0	13
157	Importance of Reporting the Gleason Score at the Positive Surgical Margin Site: Analysis of 4,082 Consecutive Radical Prostatectomy Cases. Journal of Urology, 2016, 195, 337-342.	0.4	43
158	Prospective Evaluation of 99mTc-sestamibi SPECT/CT for the Diagnosis of Renal Oncocytomas and Hybrid Oncocytic/Chromophobe Tumors. European Urology, 2016, 69, 413-416.	1.9	121
159	Should the involvement of skeletal muscle by prostatic adenocarcinoma be reported on biopsies?. Human Pathology, 2016, 49, 10-14.	2.0	1
160	Pathologic Outcomes in Favorable-risk Prostate Cancer: Comparative Analysis of Men Electing Active Surveillance and Immediate Surgery. European Urology, 2016, 69, 576-581.	1.9	42
161	African-American Men with Gleason Score 3+3=6 Prostate Cancer Produce Less Prostate Specific Antigen than Caucasian Men: A Potential Impact on Active Surveillance. Journal of Urology, 2016, 195, 301-306.	0.4	19
162	Current Histopathologic and Molecular Characterisations of Prostate Cancer: Towards Individualised Prognosis and Therapies. European Urology, 2016, 69, 186-190.	1.9	18

#	Article	IF	CITATIONS
163	A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. European Urology, 2016, 69, 428-435.	1.9	1,039
164	Combined DNA-methylation intensity and clinical risk score to stratify patients for high-grade disease Journal of Clinical Oncology, 2016, 34, 51-51.	1.6	0
165	Computer extracted nuclear features from Feulgen and H& Eimages to predict biochemical recurrence in prostate cancer patients following radical prostatectomy. Journal of Clinical Oncology, 2016, 34, 5067-5067.	1.6	0
166	Computer extracted features on H& E images to improve biochemical recurrence prediction of Kattan nomogram for prostate cancer patients following radical prostatectomy: Preliminary findings Journal of Clinical Oncology, 2016, 34, 11556-11556.	1.6	0
167	Computer aided analysis of prostate histopathology images Gleason grading especially for Gleason score 7., 2015, 2015, 3013-6.		14
168	Nonchoriocarcinomatous Trophoblastic Tumors of the Testis. American Journal of Surgical Pathology, 2015, 39, 1468-1478.	3.7	37
169	Re: Nationwide prevalence of lymph node metastases in Gleason score 3+3=6 prostate cancer. Pathology, 2015, 47, 394.	0.6	9
170	Do Clear Cell Papillary Renal Cell Carcinomas Have Malignant Potential?. American Journal of Surgical Pathology, 2015, 39, 1621-1634.	3.7	59
171	Pathological characteristics of low risk prostate cancer based on totally embedded prostatectomy specimens. Prostate, 2015, 75, 424-429.	2.3	21
172	PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas. Prostate, 2015, 75, 1610-1619.	2.3	35
173	Should Gleason 6 be labeled as cancer?. Current Opinion in Urology, 2015, 25, 238-245.	1.8	29
174	Prostate Biopsy Specimens With Gleason 3+3=6 and Intraductal Carcinoma. American Journal of Surgical Pathology, 2015, 39, 1383-1389.	3.7	73
175	Utility of PTEN and ERG Immunostaining for Distinguishing High-grade PIN From Intraductal Carcinoma of the Prostate on Needle Biopsy. American Journal of Surgical Pathology, 2015, 39, 169-178.	3.7	99
176	Development and Clinical Validation of an <i>In Situ</i> Biopsy-Based Multimarker Assay for Risk Stratification in Prostate Cancer. Clinical Cancer Research, 2015, 21, 2591-2600.	7.0	157
177	A new contemporary prostate cancer grading system. Annales De Pathologie, 2015, 35, 474-476.	0.1	17
178	The Relationship Between the Extent of Extraprostatic Extension and Survival Following Radical Prostatectomy. European Urology, 2015, 67, 342-346.	1.9	47
179	Intestinal metaplasia of the bladder with dysplasia: a risk factor for carcinoma?. Histopathology, 2015, 67, 325-330.	2.9	30
180	Handling and reporting of orchidectomy specimens with testicular cancer: areas of consensus and variation among 25 experts and 225 European pathologists. Histopathology, 2015, 67, 313-324.	2.9	41

#	Article	IF	Citations
181	Radical Prostatectomy Findings in Men on Active Surveillance: Variable Findings Dependent on Reason for Surgery and Entry Criteria. Journal of Urology, 2015, 194, 685-689.	0.4	3
182	Selective invocation of shape priors for deformable segmentation and morphologic classification of prostate cancer tissue microarrays. Computerized Medical Imaging and Graphics, 2015, 41, 3-13.	5.8	28
183	Diagnostic Challenges of Clonal Heterogeneity in Prostate Cancer. Journal of Clinical Oncology, 2015, 33, e38-e40.	1.6	48
184	Telomerase reverse transcriptase promoter mutations in glandular lesions of the urinary bladder. Annals of Diagnostic Pathology, 2015, 19, 301-305.	1.3	35
185	Risk Factors for Intraprostatic Incision into Malignant Glands at Radical Prostatectomy. European Urology, 2015, 68, 311-316.	1.9	5
186	Correlation of High Body Mass Index With More Advanced Localized Prostate Cancer at Radical Prostatectomy Is Not Reflected in PSA Level and PSA Density but Is Seen in PSA Mass. American Journal of Clinical Pathology, 2015, 144, 271-277.	0.7	15
187	Multimodal Therapy in the Treatment of Prostate Sarcoma: The Johns Hopkins Experience. Clinical Genitourinary Cancer, 2015, 13, 435-440.	1.9	12
188	Overlap of CD44 expression between prostatic small cell carcinoma and acinar adenocarcinoma. Human Pathology, 2015, 46, 554-557.	2.0	7
189	Conditional Probability of Reclassification in an Active Surveillance Program for Prostate Cancer. Journal of Urology, 2015, 193, 1950-1955.	0.4	32
190	Frozen section during partial nephrectomy: does it predict positive margins?. BJU International, 2015, 116, 868-872.	2.5	23
191	Active surveillance for prostate cancer: the role of the pathologist. Pathology, 2015, 47, 1-3.	0.6	8
192	Distinguishing Nested Variants of Urothelial Carcinoma From Benign Mimickers by TERT Promoter Mutation. American Journal of Surgical Pathology, 2015, 39, 127-131.	3.7	78
193	Smooth muscle and adenoma-like renal tumor: a previously unreported variant of mixed epithelial stromal tumor or a distinctive renal neoplasm?. Human Pathology, 2015, 46, 894-905.	2.0	7
194	Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas. Clinical Cancer Research, 2015, 21, 5619-5629.	7.0	56
195	Predictors of Adverse Pathology in Men Undergoing Radical Prostatectomy Following Initial Active Surveillance. Urology, 2015, 86, 991-997.	1.0	13
196	A subset of prostatic basal cell carcinomas harbor the MYB rearrangement of adenoid cystic carcinoma. Human Pathology, 2015, 46, 1204-1208.	2.0	34
197	A Novel Quantitative Multiplex Tissue Immunoblotting for Biomarkers Predicts a Prostate Cancer Aggressive Phenotype. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1864-1872.	2.5	13
198	Gleason 6 Prostate Cancer: Translating Biology into Population Health. Journal of Urology, 2015, 194, 626-634.	0.4	75

#	Article	IF	CITATIONS
199	Sarcomatoid Carcinoma of the Prostate: Retrospective Review of a Case Series From the Johns Hopkins Hospital. Urology, 2015, 86, 539-543.	1.0	31
200	Curvelet-based classification of prostate cancer histological images of critical Gleason scores. , 2015, , .		4
201	Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer. Journal of Clinical Oncology, 2015, 33, 3379-3385.	1.6	454
202	Invasive low-grade papillary urothelial carcinoma: an immunohistochemical study of 26 cases. Human Pathology, 2015, 46, 1836-1841.	2.0	7
203	Average Weight of Seminal Vesicles. International Journal of Surgical Pathology, 2015, 23, 617-622.	0.8	15
204	Prostate adenocarcinomas aberrantly expressing p63 are molecularly distinct from usual-type prostatic adenocarcinomas. Modern Pathology, 2015, 28, 446-456.	5 <b>.</b> 5	49
205	Extent of Extraprostatic Extension Independently Influences Biochemical Recurrence-free Survival: Evidence for Further pT3 Subclassification. Urology, 2015, 85, 161-164.	1.0	71
206	ΔNp63 (p40) expression in prostatic adenocarcinoma with diffuse p63 positivity. Human Pathology, 2015, 46, 384-389.	2.0	13
207	Update for the practicing pathologist: The International Consultation On Urologic Disease-European association of urology consultation on bladder cancer. Modern Pathology, 2015, 28, 612-630.	5 <b>.</b> 5	106
208	Magnetic Resonance–invisible Versus Magnetic Resonance–visible Prostate Cancer in Active Surveillance: AÂPreliminary Report on Disease Outcomes. Urology, 2015, 85, 147-154.	1.0	50
209	Carcinosarcomas: tumors in transition?. Histology and Histopathology, 2015, 30, 673-87.	0.7	21
210	Evaluation of early clinical experience of a novel prognostic proteomics prostate cancer biopsy test Journal of Clinical Oncology, 2015, 33, 88-88.	1.6	1
211	Sarcomatoid carcinoma of the prostate: A case series from Johns Hopkins Hospital Journal of Clinical Oncology, 2015, 33, e16105-e16105.	1.6	0
212	Consensus statement with recommendations on active surveillance inclusion criteria and definition of progression in men with localized prostate cancer: the critical role of the pathologist. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 623-628.	2.8	41
213	Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age, and stage. Modern Pathology, 2014, 27, 875-886.	5.5	136
214	The Critical Role of the Pathologist in Determining Eligibility for Active Surveillance as a Management Option in Patients With Prostate Cancer: Consensus Statement With Recommendations Supported by the College of American Pathologists, International Society of Urological Pathology, Association of Directors of Anatomic and Surgical Pathology, the New Zealand Society of Pathologists, and the Prostate Cancer Foundation. Archives of Pathology and Laboratory Medicine, 2014, 138, 1387-1405.	2.5	117
215	Diagnostic Approach to Eosinophilic Renal Neoplasms. Archives of Pathology and Laboratory Medicine, 2014, 138, 1531-1541.	2.5	106
216	Once again <scp>G</scp> leason remains the grading system to beat: a comparison with using percentage pattern 4/5. BJU International, 2014, 113, 353-354.	2.5	0

#	Article	IF	CITATIONS
217	Differences in prostate cancer grade, stage, and location in radical prostatectomy specimens from United States and Japan. Prostate, 2014, 74, 321-325.	2.3	27
218	Haemangiomas in kidneys with end-stage renal disease: a novel clinicopathological association. Histopathology, 2014, 65, 309-318.	2.9	40
219	Symplastic Leiomyomas of the Scrotum. American Journal of Surgical Pathology, 2014, 38, 1410-1417.	3.7	16
220	Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation. American Journal of Surgical Pathology, 2014, 38, 756-767.	3.7	439
221	Best Practices Recommendations in the Application of Immunohistochemistry in the Prostate. American Journal of Surgical Pathology, 2014, 38, e6-e19.	3.7	157
222	Pseudopapillary Features in Prostatic Adenocarcinoma Mimicking Urothelial Carcinoma. American Journal of Surgical Pathology, 2014, 38, 941-945.	3.7	25
223	Rosaiâ€Dorfman disease of the genitoâ€urinary tract: analysis of six cases from the testis and kidney. Histopathology, 2014, 65, 908-916.	2.9	18
224	Clinical Validation of an Epigenetic Assay to Predict Negative Histopathological Results in Repeat Prostate Biopsies. Journal of Urology, 2014, 192, 1081-1087.	0.4	196
225	When is Prostate Cancer Really Cancer?. Urologic Clinics of North America, 2014, 41, 339-346.	1.8	38
226	Idiopathic granulomatous orchitis: morphology and evaluation of its relationship to IgG4 related disease. Human Pathology, 2014, 45, 844-850.	2.0	11
227	Editorial Comment. Urology, 2014, 83, 32.	1.0	0
228	Positive Surgical Margins After Radical Prostatectomy: A Systematic Review and Contemporary Update. European Urology, 2014, 65, 303-313.	1.9	319
229	Re: Detailed Analysis of Patients with Metastasis to the Prostatic Anterior Fat Pad Lymph Nodes: A Multi-Institutional Study. Journal of Urology, 2014, 191, 559-561.	0.4	0
230	Rb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma. Clinical Cancer Research, 2014, 20, 890-903.	7.0	275
231	Testicular Swelling Due to Lymphatic Filariasis After Brief Travel to Haiti. American Journal of Tropical Medicine and Hygiene, 2014, 91, 89-91.	1.4	5
232	Ureteral and Urethral Frozen Sections During Radical Cystectomy or Cystoprostatectomy: An Analysis of Denudation and Atypia. Urology, 2014, 84, 619-623.	1.0	19
233	Variant of prostatic adenocarcinoma with Paneth cell–like neuroendocrine differentiation readily misdiagnosed as Gleason pattern 5. Human Pathology, 2014, 45, 2388-2393.	2.0	28
234	Small cell carcinoma of the prostate. Nature Reviews Urology, 2014, 11, 213-219.	3.8	187

#	Article	IF	Citations
235	Biopsy Criteria for Determining Appropriateness for Active Surveillance inÂtheÂModern Era. Urology, 2014, 83, 869-874.	1.0	95
236	Value of Transition Zone Biopsy in Active Surveillance of Prostate Cancer. Journal of Urology, 2014, 191, 1755-1759.	0.4	5
237	High-resolution transrectal ultrasound: Pilot study of a novel technique for imaging clinically localized prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 34.e27-34.e32.	1.6	35
238	Editorial Comment. Journal of Urology, 2014, 192, 102-102.	0.4	0
239	Predicting the Risk of Non–organ-confined Prostate Cancer When Perineural Invasion Is Found on Biopsy. Urology, 2014, 83, 1117-1121.	1.0	9
240	Prostate Specific Antigen Velocity Risk Count Predicts Biopsy Reclassification for Men with Very Low Risk Prostate Cancer. Journal of Urology, 2014, 191, 629-637.	0.4	28
241	Pathological Examination of Radical Prostatectomy Specimens in Men with Very Low Risk Disease at Biopsy Reveals Distinct Zonal Distribution of Cancer in Black American Men. Journal of Urology, 2014, 191, 60-67.	0.4	127
242	Prostate Cancer Early Detection, Version 1.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 1211-1219.	4.9	76
243	An updated prostate cancer staging nomogram ( $<$ scp $>$ P $<$ /scp $>$ artin tables) based on cases from 2006 to 2011. BJU International, 2013, 111, 22-29.	2.5	323
244	Expanded Criteria to Identify Men Eligible for Active Surveillance of Low Risk Prostate Cancer at Johns Hopkins: A Preliminary Analysis. Journal of Urology, 2013, 190, 2033-2038.	0.4	52
245	Pathological Outcomes in Men with Low Risk and Very Low Risk Prostate Cancer: Implications on the Practice of Active Surveillance. Journal of Urology, 2013, 190, 1218-1223.	0.4	89
246	Pathological and oncologic outcomes for men with positive lymph nodes at radical prostatectomy: The Johns Hopkins Hospital 30-year experience. Prostate, 2013, 73, 1673-1680.	2.3	51
247	Two Sequential Diagnoses of Atypical Foci Suspicious for Carcinoma on Prostate Biopsy: A Follow-up Study of 179 Cases. Urology, 2013, 82, 861-864.	1.0	6
248	Contemporary Role of Systematic Prostate Biopsies: Indications, Techniques, and Implications for Patient Care. European Urology, 2013, 63, 214-230.	1.9	214
249	Editorial Comment. Urology, 2013, 82, 152-153.	1.0	0
250	Tubulocystic carcinoma of the kidney with poorly differentiated foci: a series of 3 cases with fluorescence in situ hybridization analysis. Human Pathology, 2013, 44, 1406-1411.	2.0	40
251	Small cell–like change in prostatic intraepithelial neoplasia, intraductal carcinoma, and invasive prostatic carcinoma: a study of 7 cases. Human Pathology, 2013, 44, 427-431.	2.0	17
252	Tubular adenoma of the urinary tract: a newly described entity. Human Pathology, 2013, 44, 1890-1894.	2.0	8

#	Article	IF	Citations
253	Multiparametric magnetic resonance imaging findings in men with lowâ€risk prostate cancer followed using active surveillance. BJU International, 2013, 111, 1037-1045.	2.5	95
254	Prognostic <scp>G</scp> leason grade grouping: data based on the modified <scp>G</scp> leason scoring system. BJU International, 2013, 111, 753-760.	2.5	540
255	Cytoplasmic PTEN protein loss distinguishes intraductal carcinoma of the prostate from high-grade prostatic intraepithelial neoplasia. Modern Pathology, 2013, 26, 587-603.	5.5	129
256	Adenocarcinoma of the Prostate with Gleason Score 9-10 on Core Biopsy: Correlation with Findings at Radical Prostatectomy and Prognosis. Journal of Urology, 2013, 190, 2068-2073.	0.4	13
257	Contemporary Grading for Prostate Cancer: Implications for Patient Care. European Urology, 2013, 63, 892-901.	1.9	95
258	Pseudocarcinomatous Urothelial Hyperplasia of the Bladder: Clinical Findings and Followup of 70 Patients. Journal of Urology, 2013, 189, 2083-2086.	0.4	21
259	Common chromosomal aberrations detected by array comparative genomic hybridization in specialized stromal tumors of the prostate. Modern Pathology, 2013, 26, 1536-1543.	5.5	19
260	Gleason Score 7 Adenocarcinoma of the Prostate With Lymph Node Metastases: Analysis of 184 Radical Prostatectomy Specimens. Archives of Pathology and Laboratory Medicine, 2013, 137, 610-617.	2.5	69
261	The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. American Journal of Surgical Pathology, 2013, 37, 1469-1489.	3.7	922
262	CATA-3 Immunohistochemistry in the Differential Diagnosis of Adenocarcinoma of the Urinary Bladder. American Journal of Surgical Pathology, 2013, 37, 1756-1760.	3.7	58
263	Aberrant Expression of p63 in Adenocarcinoma of the Prostate. American Journal of Surgical Pathology, 2013, 37, 1401-1406.	3.7	44
264	Multiple cores of Gleason score 6 correlate with favourable findings at radical prostatectomy. BJU International, 2013, 111, E306-E309.	2.5	7
265	Nephrogenic Adenoma. American Journal of Surgical Pathology, 2013, 37, 532-538.	3.7	17
266	Cell Orientation Entropy (COrE): Predicting Biochemical Recurrence from Prostate Cancer Tissue Microarrays. Lecture Notes in Computer Science, 2013, 16, 396-403.	1.3	36
267	Gleason Score 6 Adenocarcinoma: Should It Be Labeled As Cancer?. Journal of Clinical Oncology, 2012, 30, 4294-4296.	1.6	162
268	Do Adenocarcinomas of the Prostate With Gleason Score (GS)â‰ <b>©</b> Have the Potential to Metastasize to Lymph Nodes?. American Journal of Surgical Pathology, 2012, 36, 1346-1352.	3.7	302
269	Invasive Low-Grade Papillary Urothelial Carcinoma. American Journal of Surgical Pathology, 2012, 36, 1081-1086.	3.7	27
270	Diagnostic issues of prostate biopsies. Case 6. PIN-like ductal adenocarcinoma. Annales De Pathologie, 2012, 32, 132-136.	0.1	3

#	Article	IF	CITATIONS
271	Gleason Pattern 5 is Frequently Underdiagnosed on Prostate Needle-core Biopsy. Urology, 2012, 79, 178-181.	1.0	20
272	Immunohistochemical pitfalls in prostate pathology. Human Pathology, 2012, 43, 313-324.	2.0	38
273	Noninvasive micropapillary urothelial carcinoma: a clinicopathologic study of 18 cases. Human Pathology, 2012, 43, 2124-2128.	2.0	31
274	Association of [â^2] proPSA with Biopsy Reclassification During Active Surveillance for Prostate Cancer. Journal of Urology, 2012, 188, 1131-1136.	0.4	115
275	Treatment decisionâ€making for localized prostate cancer: What younger men choose and why. Prostate, 2012, 72, 58-64.	2.3	93
276	A <i>IM1</i> promoter hypermethylation as a predictor of decreased risk of recurrence following radical prostatectomy. Prostate, 2012, 72, 1133-1139.	2.3	18
277	Diagnosis of limited adenocarcinoma of the prostate. Histopathology, 2012, 60, 28-40.	2.9	30
278	Upgrading and Downgrading of Prostate Cancer from Biopsy to Radical Prostatectomy: Incidence and Predictive Factors Using the Modified Gleason Grading System and Factoring in Tertiary Grades. European Urology, 2012, 61, 1019-1024.	1.9	550
279	A Contemporary Update on Pathology Reporting for Prostate Cancer: Biopsy and Radical Prostatectomy Specimens. European Urology, 2012, 62, 20-39.	1.9	85
280	Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a highâ€risk cohort of men with negative initial prostate biopsies. BJU International, 2012, 110, 56-62.	2.5	88
281	A multinational phase III adjuvant study of immediate (I) versus deferred (D) chemotherapy (C)/hormone therapy (HT) after radical prostatectomy (RP): TAX-3501 Journal of Clinical Oncology, 2012, 30, 4570-4570.	1.6	3
282	Pathology of Prostatic Neoplasia. , 2012, , 2726-2734.e3.		5
283	Cardinal Multiridgelet-based Prostate Cancer Histological Image Classification for Gleason Grading. , 2011, , .		12
284	ERG gene rearrangements are common in prostatic small cell carcinomas. Modern Pathology, 2011, 24, 820-828.	5.5	191
285	A Contemporary Analysis of Outcomes of Adenocarcinoma of the Prostate With Seminal Vesicle Invasion (pT3b) After Radical Prostatectomy. Journal of Urology, 2011, 185, 1691-1697.	0.4	70
286	Immunohistology of the Prostate, Bladder, Kidney, and Testis. , 2011, , 593-661.		6
287	Update on the Gleason grading system. Annales De Pathologie, 2011, 31, S20-S26.	0.1	13
288	Hepatocyte nuclear factor–1β expression in clear cell adenocarcinomas of the bladder and urethra: diagnostic utility and implications for histogenesis. Human Pathology, 2011, 42, 1613-1619.	2.0	38

#	Article	IF	CITATIONS
289	Papillary urothelial neoplasm of low malignant potential of the urinary bladder: clinicopathologic and outcome analysis from a single academic center. Human Pathology, 2011, 42, 1799-1803.	2.0	19
290	Interobserver Variability in Histologic Evaluation of Radical Prostatectomy Between Central and Local Pathologists: Findings of TAX 3501 Multinational Clinical Trial. Urology, 2011, 77, 1155-1160.	1.0	59
291	Prognostic Significance of Tumor Volume in Radical Prostatectomy and Needle Biopsy Specimens. Journal of Urology, 2011, 186, 790-797.	0.4	82
292	Significance of Prostate Adenocarcinoma Perineural Invasion on Biopsy in Patients Who are Otherwise Candidates for Active Surveillance. Journal of Urology, 2011, 186, 470-473.	0.4	29
293	Gleason Score 7 Prostate Cancer on Needle Biopsy: Relation of Primary Pattern 3 or 4 to Pathological Stage and Progression After Radical Prostatectomy. Journal of Urology, 2011, 186, 1286-1290.	0.4	56
294	Pathologic Stage of Prostatic Ductal Adenocarcinoma at Radical Prostatectomy. American Journal of Surgical Pathology, 2011, 35, 615-619.	3.7	49
295	Initial High-grade Prostatic Intraepithelial Neoplasia With Carcinoma on Subsequent Prostate Needle Biopsy. American Journal of Surgical Pathology, 2011, 35, 1165-1167.	3.7	21
296	Should Intervening Benign Tissue Be Included in the Measurement of Discontinuous Foci of Cancer on Prostate Needle Biopsy? Correlation With Radical Prostatectomy Findings. American Journal of Surgical Pathology, 2011, 35, 1351-1355.	3.7	66
297	Epithelial Proliferations in Prostatic Stromal Tumors of Uncertain Malignant Potential (STUMP). American Journal of Surgical Pathology, 2011, 35, 898-903.	3.7	34
298	Identification of Gleason Pattern 5 on Prostatic Needle Core Biopsy. American Journal of Surgical Pathology, 2011, 35, 1706-1711.	3.7	39
299	Large Nested Variant of Urothelial Carcinoma. American Journal of Surgical Pathology, 2011, 35, 1337-1342.	3.7	82
300	Prediction of patientâ€specific risk and percentile cohort risk of pathological stage outcome using continuous prostateâ€specific antigen measurement, clinical stage and biopsy Gleason score. BJU International, 2011, 107, 1562-1569.	2.5	36
301	The Contemporary Concept of Significant Versus Insignificant Prostate Cancer. European Urology, 2011, 60, 291-303.	1.9	267
302	The plasmacytoid carcinoma of the bladderâ€"rare variant of aggressive urothelial carcinoma. International Journal of Cancer, 2011, 129, 346-354.	5.1	94
303	International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 4: seminal vesicles and lymph nodes. Modern Pathology, 2011, 24, 39-47.	5.5	127
304	International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer volume. Modern Pathology, 2011, 24, 16-25.	5.5	214
305	International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 3: extraprostatic extension, lymphovascular invasion and locally advanced disease. Modern Pathology, 2011, 24, 26-38.	5.5	190
306	International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 1: specimen handling. Modern Pathology, 2011, 24, 6-15.	5 <b>.</b> 5	234

#	Article	IF	Citations
307	International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 5: surgical margins. Modern Pathology, 2011, 24, 48-57.	5.5	239
308	Increased gene copy number of ERG on chromosome 21 but not TMPRSS2–ERG fusion predicts outcome in prostatic adenocarcinomas. Modern Pathology, 2011, 24, 1511-1520.	5.5	57
309	Active Surveillance Program for Prostate Cancer: An Update of the Johns Hopkins Experience. Journal of Clinical Oncology, 2011, 29, 2185-2190.	1.6	545
310	SS8 Active surveillance for men with newly diagnosed prostate cancer: critical role of pathology. Japanese Journal of Urology, 2011, 102, 86.	0.1	0
311	Interobserver Reproducibility in the Diagnosis of Invasive Micropapillary Carcinoma of the Urinary Tract Among Urologic Pathologists. American Journal of Surgical Pathology, 2010, 34, 1367-1376.	3.7	111
312	Variability in Diagnostic Opinion Among Pathologists for Single Small Atypical Foci in Prostate Biopsies. American Journal of Surgical Pathology, 2010, 34, 169-177.	3.7	50
313	The FAQ Initiative Explaining Pathology Reports to Patients. American Journal of Surgical Pathology, 2010, 34, 1058-1060.	3.7	5
314	PAX8 (+)/p63 ( $\hat{a}^{\prime}$ ) Immunostaining Pattern in Renal Collecting Duct Carcinoma (CDC). American Journal of Surgical Pathology, 2010, 34, 965-969.	3.7	123
315	Rare histological patterns of prostatic ductal adenocarcinoma. Pathology, 2010, 42, 319-324.	0.6	36
316	Theranostic and prognostic biomarkers: genomic applications in urological malignancies. Pathology, 2010, 42, 384-394.	0.6	45
317	NKX3.1 as a Marker of Prostatic Origin in Metastatic Tumors. American Journal of Surgical Pathology, 2010, 34, 1097-1105.	3.7	243
318	Genitourinary pathology in the new millennium. Pathology, 2010, 42, 317-318.	0.6	0
319	Nonâ€invasive papillary urothelial neoplasms: The 2004 WHO/ISUP classification system. Pathology International, 2010, 60, 1-8.	1.3	140
320	Optimizing Performance and Interpretation of Prostate Biopsy: A Critical Analysis of the Literature. European Urology, 2010, 58, 851-864.	1.9	96
321	Fragmentation of prostatic needle biopsy cores containing adenocarcinoma: the role of specimen submission. BJU International, 2010, 105, 172-175.	2.5	24
322	Mimickers of Prostatic Intraepithelial Neoplasia. International Journal of Surgical Pathology, 2010, 18, 142-148.	0.8	7
323	Prostate-Specific Antigen Kinetics During Follow-Up Are an Unreliable Trigger for Intervention in a Prostate Cancer Surveillance Program. Journal of Clinical Oncology, 2010, 28, 2810-2816.	1.6	237
324	Clinical implications of changing definitions within the Gleason grading system. Nature Reviews Urology, 2010, 7, 136-142.	3.8	38

#	Article	IF	Citations
325	Skeletal Muscle Involvement by Limited Gleason Score 6 Adenocarcinoma of the Prostate on Needle Biopsy is Not Associated With Adverse Findings at Radical Prostatectomy. Journal of Urology, 2010, 184, 2308-2312.	0.4	11
326	Accuracy of PCA3 Measurement in Predicting Short-Term Biopsy Progression in an Active Surveillance Program. Journal of Urology, 2010, 183, 534-538.	0.4	119
327	The Value of Mandatory Second Opinion Pathology Review of Prostate Needle Biopsy Interpretation Before Radical Prostatectomy. Journal of Urology, 2010, 184, 126-130.	0.4	68
328	An Update of the Gleason Grading System. Journal of Urology, 2010, 183, 433-440.	0.4	432
329	Initial Atypical Diagnosis With Carcinoma on Subsequent Prostate Needle Biopsy: Findings at Radical Prostatectomy. Journal of Urology, 2010, 184, 1953-1957.	0.4	10
330	Small blue cells mimicking small cell carcinoma in spermatocele and hydrocele specimens: a report of 5 cases. Human Pathology, 2010, 41, 88-93.	2.0	11
331	Clear cell adenocarcinoma of the bladder and urethra: cases diffusely mimicking nephrogenic adenoma. Human Pathology, 2010, 41, 594-601.	2.0	80
332	Intraductal Carcinoma of the Prostate Without Invasive Carcinoma on Needle Biopsy: Emphasis on Radical Prostatectomy Findings. Journal of Urology, 2010, 184, 1328-1333.	0.4	192
333	Prostatic Ductal Adenocarcinoma: A Mini Review. Medical Principles and Practice, 2010, 19, 82-85.	2.4	51
334	Radical Prostatectomy: Processing, Staging, and Prognosis. Parts I and II. International Journal of Surgical Pathology, 2010, 18, 118-123.	0.8	6
335	Diagnosis and Classification of Flat, Papillary, and Invasive Urothelial Carcinoma: The WHO/ISUP Consensus. International Journal of Surgical Pathology, 2010, 18, 106-111.	0.8	16
336	The Lower Urinary Tract and Male Genital System. , 2010, , 971-1004.		29
337	Low-Grade Papillary Urothelial Carcinoma of the Urinary Bladder: A Clinicopathologic Analysis of a Post–World Health Organization/International Society of Urological Pathology Classification Cohort From a Single Academic Center. Archives of Pathology and Laboratory Medicine, 2010, 134, 1160-1163.	2.5	65
338	Precursor lesions to prostatic adenocarcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2009, 454, 1-16.	2.8	89
339	Individual and cumulative effect of prostate cancer riskâ€essociated variants on clinicopathologic variables in 5,895 prostate cancer patients. Prostate, 2009, 69, 1195-1205.	2.3	93
340	TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomas. Modern Pathology, 2009, 22, 359-365.	5.5	51
341	TMPRSS2–ERG gene fusion status in minute (minimal) prostatic adenocarcinoma. Modern Pathology, 2009, 22, 1415-1422.	5 <b>.</b> 5	48
342	Gleason grading of prostatic adenocarcinoma with glomeruloid features on needle biopsy. Human Pathology, 2009, 40, 471-477.	2.0	69

#	Article	IF	Citations
343	Urothelial carcinoma with abundant myxoid stroma. Human Pathology, 2009, 40, 1391-1398.	2.0	28
344	A pathological reassessment of organ-confined, Gleason score 6 prostatic adenocarcinomas that progress after radical prostatectomy. Human Pathology, 2009, 40, 1693-1698.	2.0	49
345	Tertiary Gleason Patterns and Biochemical Recurrence After Prostatectomy: Proposal for a Modified Gleason Scoring System. Journal of Urology, 2009, 182, 1364-1370.	0.4	87
346	Radical Prostatectomy Findings in Patients in Whom Active Surveillance of Prostate Cancer Fails. Journal of Urology, 2009, 182, 2274-2279.	0.4	131
347	High-grade Foamy Gland Prostatic Adenocarcinoma on Biopsy or Transurethral Resection. American Journal of Surgical Pathology, 2009, 33, 583-590.	3.7	34
348	Comparison of Gene Expression Profiles in Tubulocystic Carcinoma and Collecting Duct Carcinoma of the Kidney. American Journal of Surgical Pathology, 2009, 33, 1103-1106.	3.7	67
349	Detection of Cancer in Radical Prostatectomy Specimens With no Residual Carcinoma in the Initial Review of Slides. American Journal of Surgical Pathology, 2009, 33, 120-125.	3.7	25
350	Protocol for the Examination of Specimens From Patients With Carcinoma of the Prostate Gland. Archives of Pathology and Laboratory Medicine, 2009, 133, 1568-1576.	2.5	114
351	Prognostic value of Herâ€2/neu and DNA index for progression, metastasis and prostate cancerâ€specific death in men with longâ€term followâ€up after radical prostatectomy. International Journal of Cancer, 2008, 123, 2636-2643.	5.1	21
352	Bladder cancer, pathological classification and staging. BJU International, 2008, 102, 1216-1220.	2.5	32
353	Prognostic Significance of Gleason Score Discrepancies between Needle Biopsy and Radical Prostatectomy. European Urology, 2008, 53, 767-776.	1.9	77
354	Benign Mimickers of Prostate Adenocarcinoma on Needle Biopsy and Transurethral Resection. Surgical Pathology Clinics, 2008, 1, 1-41.	1.7	9
355	Mesenchymal Tumors of the Prostate. Surgical Pathology Clinics, 2008, 1, 105-128.	1.7	3
356	Prostatic adenocarcinoma in colorectal biopsy: clinical and pathologic features. Human Pathology, 2008, 39, 543-549.	2.0	32
357	Natural History of Pathologically Organ-Confined (pT2), Gleason Score 6 or Less, Prostate Cancer After Radical Prostatectomy. Urology, 2008, 72, 172-176.	1.0	73
358	A Contemporary Study Correlating Prostate Needle Biopsy and Radical Prostatectomy Gleason Score. Journal of Urology, 2008, 179, 1335-1339.	0.4	100
359	Residual Tumor Potentially Left Behind After Local Ablation Therapy in Prostate Adenocarcinoma. Journal of Urology, 2008, 179, 2203-2206.	0.4	61
360	Recommendations for the Reporting of Prostate Carcinoma. American Journal of Clinical Pathology, 2008, 129, 24-30.	0.7	39

#	Article	IF	Citations
361	Does tertiary Gleason score 5 have prognostic significance in men with prostate cancer?. Nature Reviews Urology, 2008, 5, 250-251.	1.4	1
362	The Symphonyâ,,¢ protocol for H&E staining of prostatic adenocarcinoma on needle biopsy: a multicentre analysis of 120 cases. Pathology, 2008, 40, 450-456.	0.6	3
363	Interobserver Variability Between Expert Urologic Pathologists for Extraprostatic Extension and Surgical Margin Status in Radical Prostatectomy Specimens. American Journal of Surgical Pathology, 2008, 32, 1503-1512.	3.7	123
364	False Positive Labeling of Prostate Cancer With High Molecular Weight Cytokeratin: p63 a More Specific Immunomarker for Basal Cells. American Journal of Surgical Pathology, 2008, 32, 1890-1895.	3.7	46
365	Prognosis of Mucinous Adenocarcinoma of the Prostate Treated by Radical Prostatectomy. American Journal of Surgical Pathology, 2008, 32, 468-472.	3.7	91
366	Partial Atrophy on Prostate Needle Biopsy Cores: A Morphologic and Immunohistochemical Study. American Journal of Surgical Pathology, 2008, 32, 851-857.	3.7	48
367	Grading of Invasive Cribriform Carcinoma on Prostate Needle Biopsy. American Journal of Surgical Pathology, 2008, 32, 1532-1539.	3.7	85
368	Diffuse Adenosis of the Peripheral Zone in Prostate Needle Biopsy and Prostatectomy Specimens. American Journal of Surgical Pathology, 2008, 32, 1360-1366.	3.7	23
369	Small Cell Carcinoma of the Prostate. American Journal of Surgical Pathology, 2008, 32, 65-71.	3.7	331
370	Aberrant Diffuse Expression of p63 in Adenocarcinoma of the Prostate on Needle Biopsy and Radical Prostatectomy: Report of 21 Cases. American Journal of Surgical Pathology, 2008, 32, 461-467.	3.7	95
371	Polypoid/Papillary Cystitis: A Series of 41 Cases Misdiagnosed as Papillary Urothelial Neoplasia. American Journal of Surgical Pathology, 2008, 32, 758-764.	3.7	59
372	High-grade Prostatic Intraepithelial Neoplasialike Ductal Adenocarcinoma of the Prostate: A Clinicopathologic Study of 28 Cases. American Journal of Surgical Pathology, 2008, 32, 1060-1067.	3.7	101
373	Positive Surgical Margins in Areas of Capsular Incision in Otherwise Organ-confined Disease at Radical Prostatectomy: Histologic Features and Pitfalls. American Journal of Surgical Pathology, 2008, 32, 1201-1206.	3.7	45
374	Immunohistochemical Antibody Cocktail Staining (p63/HMWCK/AMACR) of Ductal Adenocarcinoma and Gleason Pattern 4 Cribriform and Noncribriform Acinar Adenocarcinomas of the Prostate. American Journal of Surgical Pathology, 2007, 31, 889-894.	3.7	89
375	The Role of P501S and PSA in the Diagnosis of Metastatic Adenocarcinoma of the Prostate. American Journal of Surgical Pathology, 2007, 31, 1351-1355.	3.7	95
376	Immunohistochemical Differentiation of High-grade Prostate Carcinoma From Urothelial Carcinoma. American Journal of Surgical Pathology, 2007, 31, 1246-1255.	3.7	192
377	Detection of Residual Tumor Cells in Bladder Biopsy Specimens: Pitfalls in the Interpretation of Cytokeratin Stains. American Journal of Surgical Pathology, 2007, 31, 390-397.	3.7	29
378	Significance of Denuded Urothelium in Papillary Urothelial Lesions. American Journal of Surgical Pathology, 2007, 31, 298-303.	3.7	19

#	Article	IF	CITATIONS
379	Fibromyxoid Nephrogenic Adenoma: A Newly Recognized Variant Mimicking Mucinous Adenocarcinoma. American Journal of Surgical Pathology, 2007, 31, 1231-1237.	3.7	59
380	Primary Mucin-producing Urothelial-type Adenocarcinoma of Prostate: Report of 15 Cases. American Journal of Surgical Pathology, 2007, 31, 1323-1329.	3.7	72
381	Recommendations for the reporting of prostate carcinoma. Human Pathology, 2007, 38, 1305-1309.e4.	2.0	43
382	The Significance of Positive Surgical Margin in Areas of Capsular Incision in Otherwise Organ Confined Disease at Radical Prostatectomy. Journal of Urology, 2007, 178, 1306-1310.	0.4	94
383	Expectant Management of Prostate Cancer With Curative Intent: An Update of The Johns Hopkins Experience. Journal of Urology, 2007, 178, 2359-2365.	0.4	308
384	Significant variations in nuclear structure occur between and within Gleason grading patterns 3, 4, and 5 determined by digital image analysis. Prostate, 2007, 67, 1202-1210.	2.3	23
385	Spindle cell lesions of the adult prostate. Modern Pathology, 2007, 20, 148-158.	5 <b>.</b> 5	139
386	Lymphoepithelioma-like carcinoma of the urinary tract: a clinicopathological study of 30 pure and mixed cases. Modern Pathology, 2007, 20, 828-834.	5 <b>.</b> 5	114
387	Recommendations for the reporting of prostate carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2007, 451, 751-756.	2.8	7
388	Neoplasms of the Prostate and Seminal Vesicles. , 2007, , 56-108.		1
389	Prostate Needle Biopsies Containing Prostatic Intraepithelial Neoplasia or Atypical Foci Suspicious for Carcinoma: Implications for Patient Care. Journal of Urology, 2006, 175, 820-834.	0.4	372
390	Risk of Prostate Cancer on First Re-Biopsy Within 1 Year Following a Diagnosis of High Grade Prostatic Intraepithelial Neoplasia is Related to the Number of Cores Sampled. Journal of Urology, 2006, 175, 121-124.	0.4	101
391	Current practice of diagnosis and reporting of prostate cancer on needle biopsy among genitourinary pathologists. Human Pathology, 2006, 37, 292-297.	2.0	49
392	Inverted urothelial papillomas with foamy or vacuolated cytoplasm. Human Pathology, 2006, 37, 1577-1582.	2.0	20
393	Relationship between primary Gleason pattern on needle biopsy and clinicopathologic outcomes among men with Gleason score 7 adenocarcinoma of the prostate. Urology, 2006, 67, 115-119.	1.0	34
394	Is high-grade prostatic intraepithelial neoplasia on needle biopsy different in an Asian population: A clinicopathologic study performed in Singapore. Urology, 2006, 68, 800-803.	1.0	21
395	Sarcomatoid Carcinoma of the Prostate: A Study of 42 Cases. American Journal of Surgical Pathology, 2006, 30, 1316-1321.	3.7	107
396	Widespread High-grade Prostatic Intraepithelial Neoplasia on Prostatic Needle Biopsy: A Significant Likelihood of Subsequently Diagnosed Adenocarcinoma. American Journal of Surgical Pathology, 2006, 30, 1184-1188.	3.7	87

#	Article	IF	CITATIONS
397	Prognostic Significance of Paneth Cell-like Neuroendocrine Differentiation in Adenocarcinoma of the Prostate. American Journal of Surgical Pathology, 2006, 30, 980-985.	3.7	73
398	Inverted Papillomas of the Prostatic Urethra. American Journal of Surgical Pathology, 2006, 30, 975-979.	3.7	31
399	Specialized Stromal Tumors of the Prostate: A Clinicopathologic Study of 50 Cases. American Journal of Surgical Pathology, 2006, 30, 694-704.	3.7	156
400	Update on the Gleason Grading System for Prostate Cancer. Advances in Anatomic Pathology, 2006, 13, 57-59.	4.3	108
401	Expanding the Histologic Spectrum of Mucinous Tubular and Spindle Cell Carcinoma of the Kidney. American Journal of Surgical Pathology, 2006, 30, 1554-1560.	3.7	125
402	What???s new in prostate cancer disease assessment in 2006?. Current Opinion in Urology, 2006, 16, 146-151.	1.8	26
403	Pleomorphic Giant Cell Adenocarcinoma of the Prostate. American Journal of Surgical Pathology, 2006, 30, 1254-1259.	3.7	56
404	Osteoclast-rich undifferentiated carcinomas of the urinary tract. Modern Pathology, 2006, 19, 161-171.	5 <b>.</b> 5	94
405	Intraductal carcinoma of the prostate on needle biopsy: histologic features and clinical significance. Modern Pathology, 2006, 19, 1528-1535.	5 <b>.</b> 5	298
406	Updated Protocol for the Examination of Specimens From Patients With Carcinomas of the Prostate Gland. Archives of Pathology and Laboratory Medicine, 2006, 130, 936-946.	2.5	49
407	Small Glandular Proliferations on Needle Biopsies. American Journal of Surgical Pathology, 2005, 29, 874-880.	3.7	71
408	Perineural Involvement by Benign Prostatic Glands on Needle Biopsy. American Journal of Surgical Pathology, 2005, 29, 1159-1163.	3.7	41
409	The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. American Journal of Surgical Pathology, 2005, 29, 1228-1242.	3.7	2,334
410	Little or No Residual Prostate Cancer at Radical Prostatectomy: Vanishing Cancer or Switched Specimen?. American Journal of Surgical Pathology, 2005, 29, 467-473.	3.7	49
411	Clear Cell Papillary Cystadenoma of the Epididymis and Mesosalpinx. American Journal of Surgical Pathology, 2005, 29, 520-523.	3.7	68
412	Minute Foci of Gleason Score 8-10 on Prostatic Needle Biopsy. American Journal of Surgical Pathology, 2005, 29, 962-968.	3.7	11
413	Prognostic and predictive factors and reporting of prostate carcinoma in prostate needle biopsy specimens. Scandinavian Journal of Urology and Nephrology, 2005, 39, 20-33.	1.4	114
414	Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens. Scandinavian Journal of Urology and Nephrology, 2005, 39, 34-63.	1.4	194

#	Article	IF	CITATIONS
415	PATIENT AND UROLOGIST DRIVEN SECOND OPINION OF PROSTATE NEEDLE BIOPSIES. Journal of Urology, 2005, 174, 1390-1394.	0.4	29
416	PREDICTION OF EXTRAPROSTATIC EXTENSION IN THE NEUROVASCULAR BUNDLE BASED ON PROSTATE NEEDLE BIOPSY PATHOLOGY, SERUM PROSTATE SPECIFIC ANTIGEN AND DIGITAL RECTAL EXAMINATION. Journal of Urology, 2005, 173, 450-453.	0.4	80
417	Current practice of Gleason grading among genitourinary pathologists. Human Pathology, 2005, 36, 5-9.	2.0	52
418	Basal cell hyperplasia: an unusual diagnostic dilemma on prostate needle biopsies. Human Pathology, 2005, 36, 480-485.	2.0	43
419	Number and location of nucleoli and presence of apoptotic bodies in diagnostically challenging cases of prostate adenocarcinoma on needle biopsy. Human Pathology, 2005, 36, 1172-1177.	2.0	14
420	Utility of saturation biopsy to predict insignificant cancer at radical prostatectomy. Urology, 2005, 66, 356-360.	1.0	161
421	UROTHELIAL NEOPLASMS IN PATIENTS 20 YEARS OR YOUNGER: A CLINICOPATHOLOGICAL ANALYSIS USING THE WORLD HEALTH ORGANIZATION 2004 BLADDER CONSENSUS CLASSIFICATION. Journal of Urology, 2005, 174, 1976-1980.	0.4	110
422	Diagnosis and reporting of limited adenocarcinoma of the prostate on needle biopsy. Modern Pathology, 2004, 17, 307-315.	5.5	109
423	Biochemical failure after radical prostatectomy in men with pathologic organ-confined disease: pT2a versus pT2b. Cancer, 2004, 100, 1646-1649.	4.1	61
424	Characteristics of insignificant clinical T1c prostate tumors. Cancer, 2004, 101, 2001-2005.	4.1	213
425	Pathological and molecular mechanisms of prostate carcinogenesis: Implications for diagnosis, detection, prevention, and treatment. Journal of Cellular Biochemistry, 2004, 91, 459-477.	2.6	164
426	Positive proximal (bladder neck) margin at radical prostatectomy confers greater risk of biochemical progression. Urology, 2004, 64, 551-555.	1.0	76
427	Negative 34βE12 staining in a small focus of atypical glands on prostate needle biopsy: a follow-up study of 332 cases. Human Pathology, 2004, 35, 43-46.	2.0	16
428	Use of interphase fluorescence in situ hybridization in prostate needle biopsy specimens with isolated high-grade prostatic intraepithelial neoplasia as a predictor of prostate adenocarcinoma on follow-up biopsy. Human Pathology, 2004, 35, 281-289.	2.0	15
429	Utility of immunohistochemistry for $\hat{l}_{\pm}$ -methylacyl-CoA racemase in distinguishing atrophic prostate cancer from benign atrophy. Human Pathology, 2004, 35, 1272-1278.	2.0	72
430	Atypia in inverted urothelial papillomas: Pathology and prognostic significance. Human Pathology, 2004, 35, 1499-1504.	2.0	47
431	The Prognostic Significance of Tertiary Gleason Pattern 5 in Radical Prostatectomy Specimens. American Journal of Surgical Pathology, 2004, 28, 394-398.	3.7	90
432	High-grade Prostatic Intraepithelial Neoplasia on Needle Biopsy. American Journal of Surgical Pathology, 2004, 28, 629-633.	3.7	86

#	Article	IF	Citations
433	How Often Does Alpha-Methylacyl-CoA-Racemase Contribute to Resolving an Atypical Diagnosis on Prostate Needle Biopsy Beyond That Provided by Basal Cell Markers?. American Journal of Surgical Pathology, 2004, 28, 239-243.	3.7	116
434	ALK-1 Expression in Inflammatory Myofibroblastic Tumor of the Urinary Bladder. American Journal of Surgical Pathology, 2004, 28, 1609-1614.	3.7	145
435	Quantitative alterations in nuclear structure predict prostate carcinoma distant metastasis and death in men with biochemical recurrence after radical prostatectomy. Cancer, 2003, 98, 2583-2591.	4.1	39
436	The new World Health Organization/International Society of Urological Pathology (WHO/ISUP) classification for TA, T1 bladder tumors: is it an improvement?. Critical Reviews in Oncology/Hematology, 2003, 47, 83-89.	4.4	66
437	Lesions missed on prostate biopsies in cases sent in for consultation. Prostate, 2003, 54, 310-314.	2.3	28
438	Correlation Of Minute (0.5 MM or Less) Focus of Prostate Adenocarcinoma On Needle Biopsy With Radical Prostatectomy Specimen: Role of Prostate Specific Antigen Density. Journal of Urology, 2003, 170, 370-372.	0.4	107
439	Can Prostate Specific Antigen Derivatives and Pathological Parameters Predict Significant Change in Expectant Management Criteria for Prostate Cancer?. Journal of Urology, 2003, 170, 2274-2278.	0.4	71
440	Biochemical (Prostate Specific Antigen) Recurrence Probability Following Radical Prostatectomy for Clinically Localized Prostate Cancer. Journal of Urology, 2003, 169, 517-523.	0.4	691
441	Should each core with prostate cancer be assigned a separate gleason score?. Human Pathology, 2003, 34, 911-914.	2.0	61
442	α-Methylacyl-CoA Racemase. American Journal of Surgical Pathology, 2003, 27, 1128-1133.	3.7	120
443	Florid von Brunn Nests Mimicking Urothelial Carcinoma. American Journal of Surgical Pathology, 2003, 27, 1243-1252.	3.7	131
444	Expression and Diagnostic Utility of Alpha-Methylacyl-CoA-Racemase (P504S) in Foamy Gland and Pseudohyperplastic Prostate Cancer. American Journal of Surgical Pathology, 2003, 27, 772-778.	3.7	128
445	Can Basal Cells Be Seen in Adenocarcinoma of the Prostate?. American Journal of Surgical Pathology, 2002, 26, 1151-1160.	3.7	90
446	Gleason Score 7 Prostate Cancer on Needle Biopsy: Is the Prognostic Difference in Gleason Scores 4 3 and 3 4 Independent of the Number of Involved Cores?. Journal of Urology, 2002, 167, 2440-2442.	0.4	90
447	Prediction of outcome after radical prostatectomy in men with organ-confined Gleason score 8 to 10 adenocarcinoma. Urology, 2002, 60, 666-669.	1.0	26
448	Prognostic significance of atypical papillary urothelial hyperplasia. Human Pathology, 2002, 33, 512-517.	2.0	30
449	Central zone histology of the prostate: A mimicker of high-grade prostatic intraepithelial neoplasia. Human Pathology, 2002, 33, 518-523.	2.0	40
450	EXPECTANT MANAGEMENT OF NONPALPABLE PROSTATE CANCER WITH CURATIVE INTENT: PRELIMINARY RESULTS. Journal of Urology, 2002, 167, 1231-1234.	0.4	203

#	Article	IF	CITATIONS
451	Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4 + 3 and 3 + 4 independent of the number of involved cores?. Journal of Urology, 2002, 167, 2440-2.	0.4	27
452	Interobserver reproducibility of Gleason grading of prostatic carcinoma: Urologic pathologists. Human Pathology, 2001, 32, 74-80.	2.0	280
453	Interobserver reproducibility of Gleason grading of prostatic carcinoma: General pathologist. Human Pathology, 2001, 32, 81-88.	2.0	334
454	High-grade prostatic intraepithelial neoplasia with adjacent small atypical glands on prostate biopsy. Human Pathology, 2001, 32, 389-395.	2.0	77
455	Low-grade myxoid renal epithelial neoplasms with distal nephron differentiation. Human Pathology, 2001, 32, 506-512.	2.0	129
456	Comparative analysis of sampling methods for grossing radical prostatectomy specimens performed for nonpalpable (stage T1c) prostatic adenocarcinoma. Human Pathology, 2001, 32, 494-499.	2.0	82
457	Importance of posterolateral needle biopsies in the detection of prostate cancer. Urology, 2001, 57, 1112-1116.	1.0	80
458	Does capsular incision at radical retropubic prostatectomy affect disease-free survival in otherwise organ-confined prostate cancer?. Urology, 2001, 58, 746-751.	1.0	71
459	Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology, 2001, 58, 843-848.	1.0	943
460	ERA SPECIFIC BIOCHEMICAL RECURRENCE-FREE SURVIVAL FOLLOWING RADICAL PROSTATECTOMY FOR CLINICALLY LOCALIZED PROSTATE CANCER. Journal of Urology, 2001, 166, 416-419.	0.4	266
461	LONG-TERM BIOCHEMICAL DISEASE-FREE AND CANCER-SPECIFIC SURVIVAL FOLLOWING ANATOMIC RADICAL RETROPUBIC PROSTATECTOMY. Urologic Clinics of North America, 2001, 28, 555-565.	1.8	939
462	CLINICAL SIGNIFICANCE OF DENUDED UROTHELIUM IN BLADDER BIOPSY. Journal of Urology, 2001, 166, 457-460.	0.4	23
463	ISOLATED LOCAL RECURRENCE IS RARE AFTER RADICAL PROSTATECTOMY IN MEN WITH GLEASON 7 PROSTATE CANCER AND POSITIVE SURGICAL MARGINS: THERAPEUTIC IMPLICATIONS. Journal of Urology, 2001, 165, 864-866.	0.4	30
464	DEDIFFERENTIATION OF PROSTATE CANCER GRADE WITH TIME IN MEN FOLLOWED EXPECTANTLY FOR STAGE T1C DISEASE. Journal of Urology, 2001, 166, 1688-1691.	0.4	81
465	THE PATHOLOGICAL INTERPRETATION AND SIGNIFICANCE OF PROSTATE NEEDLE BIOPSY FINDINGS: IMPLICATIONS AND CURRENT CONTROVERSIES. Journal of Urology, 2001, 166, 402-410.	0.4	140
466	In Situ Adenocarcinoma of the Bladder. American Journal of Surgical Pathology, 2001, 25, 892-899.	3.7	55
467	Atypical Cribriform Lesions on Prostate Biopsy. American Journal of Surgical Pathology, 2001, 25, 147-155.	3.7	25
468	A Clinicopathologic Analysis of Urothelial Carcinomas Diagnosed on Prostate Needle Biopsy. American Journal of Surgical Pathology, 2001, 25, 794-801.	3.7	47

#	Article	IF	CITATIONS
469	Inverted (Hobnail) High-Grade Prostatic Intraepithelial Neoplasia (PIN). American Journal of Surgical Pathology, 2001, 25, 1534-1539.	3.7	30
470	Predicting Cancer Following a Diagnosis of High-Grade Prostatic Intraepithelial Neoplasia on Needle Biopsy. American Journal of Surgical Pathology, 2001, 25, 1079-1085.	3.7	192
471	Correlation of Ki-67 and p53 With the New World Health Organization/International Society of Urological Pathology Classification System for Urothelial Neoplasia. Archives of Pathology and Laboratory Medicine, 2001, 125, 646-651.	2.5	70
472	Genetic Alterations in Urinary Bladder Carcinosarcoma: Evidence of a Common Clonal Origin. European Urology, 2000, 37, 350-357.	1.9	54
473	The Prognostic Significance of Tertiary Gleason Patterns of Higher Grade in Radical Prostatectomy Specimens. American Journal of Surgical Pathology, 2000, 24, 563-569.	3.7	195
474	Infarct of the Prostate Gland. American Journal of Surgical Pathology, 2000, 24, 1378-1384.	3.7	29
475	Foamy Gland High-Grade Prostatic Intraepithelial Neoplasia. American Journal of Surgical Pathology, 2000, 24, 140.	3.7	39
476	Gleason Score 2–4 Adenocarcinoma of the Prostate on Needle Biopsy. American Journal of Surgical Pathology, 2000, 24, 477-478.	3.7	205
477	Extensively Necrotic Cystic Renal Cell Carcinoma. American Journal of Surgical Pathology, 2000, 24, 988-995.	3.7	80
478	Pseudohyperplastic Prostatic Adenocarcinoma on Needle Biopsy and Simple Prostatectomy. American Journal of Surgical Pathology, 2000, 24, 1039-1046.	3.7	70
479	Author reply. Cancer, 2000, 89, 226-226.	4.1	0
480	A web-based tutorial improves practicing pathologists' Gleason grading of images of prostate carcinoma specimens obtained by needle biopsy. Cancer, 2000, 89, 1818-1823.	4.1	86
481	Molecular and immunohistochemical staging of men with seminal vesicle invasion and negative pelvic lymph nodes at radical prostatectomy. Cancer, 2000, 89, 2577-2586.	4.1	37
482	Papillary urothelial hyperplasia is a clonal precursor to papillary transitional cell bladder cancer. International Journal of Cancer, 2000, 89, 514-518.	5.1	88
483	Needle Biopsy of Recurrent Adenocarcinoma of the Prostate After Radical Prostatectomy. Modern Pathology, 2000, 13, 521-527.	5.5	6
484	Adenocarcinoma of the prostate invading the seminal vesicle: prognostic stratification based on pathologic parameters. Urology, 2000, 56, 283-288.	1.0	148
485	Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology, 2000, 56, 823-827.	1.0	298
486	EFFECTS OF A SAW PALMETTO HERBAL BLEND IN MEN WITH SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA. Journal of Urology, 2000, 163, 1451-1456.	0.4	128

#	Article	IF	CITATIONS
487	A webâ€based tutorial improves practicing pathologists' Gleason grading of images of prostate carcinoma specimens obtained by needle biopsy. Cancer, 2000, 89, 1818-1823.	4.1	2
488	Molecular and immunohistochemical staging of men with seminal vesicle invasion and negative pelvic lymph nodes at radical prostatectomy. Cancer, 2000, 89, 2577-2586.	4.1	1
489	Papillary urothelial hyperplasia is a clonal precursor to papillary transitional cell bladder cancer. International Journal of Cancer, 2000, 89, 514-518.	5.1	3
490	Mandatory second opinion surgical pathology at a large referral hospital. Cancer, 1999, 86, 2426-2435.	4.1	275
491	Nuclear morphometry predicts disease-free interval for clinically localized adenocarcinoma of the prostate treated with definitive radiation therapy. International Journal of Cancer, 1999, 84, 594-597.	5.1	13
492	Bioimpedance: Novel use of a minimally invasive technique for cancer localization in the intact prostate., 1999, 39, 213-218.		57
493	Monoclonal antibody to prostate cancer nuclear matrix protein (PRO:4-216) recognizes nucleophosmin/B23., 1999, 39, 298-304.		100
494	CAN PLOIDY OF PROSTATE CARCINOMA DIAGNOSED ON NEEDLE BIOPSY PREDICT RADICAL PROSTATECTOMY STAGE AND GRADE?. Journal of Urology, 1999, 162, 2036-2039.	0.4	32
495	Follow-up of atypical prostate needle biopsies suspicious for cancer. Urology, 1999, 53, 351-355.	1.0	147
496	Genetically engineered neural networks for predicting prostate cancer progression after radical prostatectomy. Urology, 1999, 54, 791-795.	1.0	78
497	THE SIGNIFICANCE OF PRIOR BENIGN NEEDLE BIOPSIES IN MEN SUBSEQUENTLY DIAGNOSED WITH PROSTATE CANCER. Journal of Urology, 1999, 162, 1649-1652.	0.4	46
498	Mandatory second opinion surgical pathology at a large referral hospital. Cancer, 1999, 86, 2426-2435.	4.1	6
499	Perineural Invasion, Mucinous Fibroplasia, and Glomerulations. American Journal of Surgical Pathology, 1999, 23, 918.	3.7	70
500	Ductal Adenocarcinoma of the Prostate Diagnosed on Needle Biopsy. American Journal of Surgical Pathology, 1999, 23, 1471.	3.7	138
501	The Gleason Grading System: An Overview. Journal of Urologic Pathology, 1999, 10, 141-158.	0.3	38
502	Immunoreactivity for prostate-specific antigen and prostatic acid phosphatase in adenocarcinoma of the prostate: Relation to progression following radical prostatectomy., 1998, 34, 29-33.		8
503	CD44 and CD44v6 downregulation in clinical prostatic carcinoma: Relation to Gleason grade and cytoarchitecture., 1998, 34, 162-168.		85
504	Diagnoses rendered on prostate needle biopsy in community hospitals., 1998, 35, 50-55.		27

#	Article	IF	Citations
505	DISEASE PROGRESSION FOLLOWING RADICAL PROSTATECTOMY IN MEN WITH GLEASON SCORE 7 TUMOR. Journal of Urology, 1998, 160, 97-101.	0.4	84
506	Ability of Sextant Biopsies to Predict Radical Prostatectomy Stage. Urology, 1998, 51, 759-764.	1.0	127
507	Repeat biopsy strategies for men with atypical diagnoses on initial prostate needle biopsy. Urology, 1998, 52, 803-807.	1.0	84
508	ANALYSIS OF THE PROSTATIC CENTRAL ZONE IN PATIENTS WITH UNILATERAL ABSENCE OF WOLFFIAN DUCT STRUCTURES: FURTHER EVIDENCE OF THE MESODERMAL ORIGIN OF THE PROSTATIC CENTRAL ZONE. Journal of Urology, 1998, 160, 2126-2129.	0.4	16
509	CD44 and CD44v6 downregulation in clinical prostatic carcinoma: Relation to Gleason grade and cytoarchitecture. Prostate, 1998, 34, 162-168.	2.3	1
510	Sarcomas and Related Proliferative Lesions of Specialized Prostatic Stroma. American Journal of Surgical Pathology, 1998, 22, 148-162.	3.7	188
511	Partial Atrophy in Prostate Needle Cores. American Journal of Surgical Pathology, 1998, 22, 440-445.	3.7	54
512	The World Health Organization/International Society of Urological Pathology Consensus Classification of Urothelial (Transitional Cell) Neoplasms of the Urinary Bladder. American Journal of Surgical Pathology, 1998, 22, 1435-1448.	3.7	1,417
513	Prospective Evaluation of Men With Stage T1C Adenocarcinoma of the Prostate. Journal of Urology, 1997, 157, 2206-2209.	0.4	167
514	Do Close but Negative Margins in Radical Prostatectomy Specimens Increase the Risk of Postoperative Progression?. Journal of Urology, 1997, 157, 241-243.	0.4	82
515	USE OF REPEAT SEXTANT AND TRANSITION ZONE BIOPSIES FOR ASSESSING EXTENT OF PROSTATE CANCER. Journal of Urology, 1997, 158, 1886-1890.	0.4	173
516	Incidence and clinical significance of high-grade prostatic intraepithelial neoplasia in turp specimens. Urology, 1997, 49, 558-563.	1.0	48
517	Incidence of high-grade prostatic intraepithelial neoplasia in sextant needle biopsy specimens. Urology, 1997, 49, 367-373.	1.0	103
518	Differentiation of colonic metaplasia from adenocarcinoma of urinary bladder. Human Pathology, 1997, 28, 1152-1157.	2.0	44
519	Primary intracerebral small-cell osteosarcoma in an adolescent girl: report of a case. Journal of Neuro-Oncology, 1997, 32, 169-174.	2.9	16
520	Prediction of significant cancer in men with stage Tic adenocarcinoma of the prostate. World Journal of Urology, 1997, 15, 359-363.	2.2	15
521	Radical prostatectomy as treatment for prostate-specific antigen-detected stage T1c prostate cancer. World Journal of Urology, 1997, 15, 373-377.	2.2	24
522	Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in gleason sum 5 to 7 adenocarcinoma of the prostate., 1997, 79, 772-779.		179

#	Article	IF	Citations
523	Increasing Incidence of Minimal Residual Cancer In Radical Prostatectomy Specimens. American Journal of Surgical Pathology, 1997, 21, 174-178.	3.7	93
524	Adenocarcinoma of the Prostate with Atrophic Features. American Journal of Surgical Pathology, 1997, 21, 289-295.	3.7	62
525	Diagnosis of Cowper's Glands on Prostate Needle Biopsy. American Journal of Surgical Pathology, 1997, 21, 550-555.	3.7	40
526	Correlation of Prostate Needle Biopsy and Radical Prostatectomy Gleason Grade in Academic and Community Settings. American Journal of Surgical Pathology, 1997, 21, 566-576.	3.7	354
527	The Significance of Intraluminal Crystalloids in Benign Prostatic Glands on Needle Biopsy. American Journal of Surgical Pathology, 1997, 21, 725-728.	3.7	50
528	Critical issues in grading of adenocarcinomas of the prostate. Canadian Journal of Urology, 1997, 4, 28-33.	0.0	0
529	Ureteral Frozen Section Analysis During Cystectomy: A Reassessment. Journal of Urology, 1996, 155, 1218-1220.	0.4	59
530	Ability to predict biochemical progression using gleason score and a computer-generated quantitative nuclear grade derived from cancer cell nuclei. Urology, 1996, 48, 685-691.	1.0	46
531	Neuroendocrine differentiation in prostate cancer: Enhanced prediction of progression after radical prostatectomy. Human Pathology, 1996, 27, 683-687.	2.0	180
532	Extended Followup of the Influence of Wide Excision of the Neurovascular Bundle(s) on Prognosis in Men with Clinically Localized Prostate Cancer and Extensive Capsular Perforation. Journal of Urology, 1996, 156, 454-458.	0.4	79
533	Characterization of prostatic basal cell hyperplasia and neoplasia in aged macaques: Comparative pathology in human and nonhuman primates., 1996, 29, 51-59.		18
534	The diagnosis and reporting of adenocarcinoma of the prostate in core needle biopsy specimens. , 1996, 78, 350-356.		48
535	Workgroup 5: Assessment of prostate carcinoma in core needle biopsy-Definition of minimal criteria for the diagnosis of cancer in biopsy material. Cancer, 1996, 78, 376-381.	4.1	90
536	Workgroup 5: Assessment of prostate carcinoma in core needle biopsyâ€â€Definition of minimal criteria for the diagnosis of cancer in biopsy material. Cancer, 1996, 78, 376-381.	4.1	4
537	Prediction of Progression Following Radical Prostatectomy. American Journal of Surgical Pathology, 1996, 20, 286-292.	3.7	532
538	Prostatic Carcinoma with Abundant Xanthomatous Cytoplasm. American Journal of Surgical Pathology, 1996, 20, 419-426.	3.7	100
539	Clinical and Cost Impact of Second-opinion Pathology. American Journal of Surgical Pathology, 1996, 20, 851-857.	3.7	174
540	Papillary Urothelial Hyperplasia. American Journal of Surgical Pathology, 1996, 20, 1481-1488.	3.7	63

#	Article	IF	CITATIONS
541	The Utility of Basal Cellâ€"Specific Anti-Cytokeratin Antibody (34βE12) in the Diagnosis of Prostate Cancer. American Journal of Surgical Pathology, 1995, 19, 251-260.	3.7	208
542	Interobserver Reproducibility in the Diagnosis of Prostatic Intraepithelial Neoplasia. American Journal of Surgical Pathology, 1995, 19, 873-886.	3.7	142
543	Frequent Loss of Chromosome Arms 8p and 13q in Collecting Duct Carcinoma (CDC) of the Kidney. Genes Chromosomes and Cancer, 1995, 12, 76-80.	2.8	75
544	Utilization of high molecular weight cytokeratin on prostate needle biopsies in an independent laboratory. Urology, 1995, 45, 981-986.	1.0	72
545	Original Articles: Prostate Cancer: Deoxyribonucleic Acid Ploidy Analysis as a Predictor of Recurrence Following Radical Prostatectomy for Stage T2 Disease. Journal of Urology, 1995, 153, 1015-1019.	0.4	44
546	Intraoperative Sonography for the Evaluation and Management of Renal Tumors: Experience with 100 Patients. Journal of Urology, 1995, 154, 1676-1680.	0.4	73
547	Pathologic and Clinical Findings to Predict Tumor Extent of Nonpalpable (Stage T1 c) Prostate Cancer. JAMA - Journal of the American Medical Association, 1994, 271, 368.	7.4	1,325
548	Small High Grade Adenocarcinoma of the Prostate in Radical Prostatectomy Specimens Performed for Nonpalpable Disease: Pathogenetic and Clinical Implications. Journal of Urology, 1994, 151, 1587-1592.	0.4	87
549	Cancer Control and Quality of Life Following Anatomical Radical Retropubic Prostatectomy: Results at 10 Years. Journal of Urology, 1994, 152, 1831-1836.	0.4	650
550	Prognostic Factors in Men with Stage D1 Prostate Cancer: Identification of Patients Less Likely to Have Prolonged Survival After Radical Prostatectomy. Journal of Urology, 1994, 152, 1077-1081.	0.4	95
551	Radical Prostatectomy for Impalpable Prostate Cancer: The Johns Hopkins Experience With Tumors Found on Transurethral Resection (Stages T1a and T1b) and on Needle Biopsy (Stage T1c). Journal of Urology, 1994, 152, 1721-1729.	0.4	133
552	Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer, 1993, 71, 3582-3593.	4.1	709
553	Significance of high-grade prostatic intraepithelial neoplasia on needle biopsy. Human Pathology, 1993, 24, 624-629.	2.0	164
554	Influence of Capsular Penetration on Progression Following Radical Prostatectomy: A Study of 196 Cases with Long-Term Followup. Journal of Urology, 1993, 150, 135-141.	0.4	353
555	Influence of Wide Excision of the Neurovascular Bundle(s) on Prognosis in Men with Clinically Localized Prostate Cancer with Established Capsular Penetration. Journal of Urology, 1993, 150, 142-146.	0.4	105
556	Is Tumor Volume an Independent Predictor of Progression Following Radical Prostatectomy? A Multivariate Analysis of 185 Clinical Stage B Adenocarcinomas of the Prostate with 5 Years of Followup. Journal of Urology, 1993, 149, 1478-1481.	0.4	314
557	Does High Grade Prostatic Intraepithelial Neoplasia Result in Elevated Serum Prostate Specific Antigen levels?. Journal of Urology, 1993, 150, 386-389.	0.4	84
558	Relationship Between Perineural Tumor Invasion on Needle Biopsy and Radical Prostatectomy Capsular Penetration in Clinical Stage B Adenocarcinoma of the Prostate. American Journal of Surgical Pathology, 1993, 17, 336-341.	3.7	164

#	Article	IF	CITATIONS
559	Adenocarcinoma of the Colon Simulating Primary Urinary Bladder Neoplasia. American Journal of Surgical Pathology, 1993, 17, 171-178.	3.7	46
560	PSA AND PAP AS IMMUNOHISTOCHEMICAL MARKERS IN PROSTATE CANCER. Urologic Clinics of North America, 1993, 20, 757-770.	1.8	69
561	A Quantitative Histological Analysis of the Dilated Ureter of Childhood. Journal of Urology, 1992, 148, 1482-1486.	0.4	46
562	Evaluation of Radical Prostatectomy Specimens. American Journal of Surgical Pathology, 1992, 16, 315-324.	3.7	169
563	Atypical Basal Cell Hyperplasia of the Prostate. American Journal of Surgical Pathology, 1992, 16, 1205-1214.	3.7	80
564	Acidic mucin in the prostate: Can it differentiate adenosis from adenocarcinoma?. Human Pathology, 1992, 23, 1321-1325.	2.0	41
565	Current and proposed biologic markers in prostate cancer. Journal of Cellular Biochemistry, 1992, 50, 65-67.	2.6	11
566	Prediction of prognosis in untreated stage A2 prostatic carcinoma. Cancer, 1992, 69, 511-519.	4.1	47
567	Use of nuclear morphometry, gleason histologic scoring, clinical stage, and age to predict disease-free survival among patients with prostate cancer. Cancer, 1992, 70, 161-168.	4.1	107
568	Evaluation of Radical Prostatectomy Capsular Margins of Resection. American Journal of Surgical Pathology, 1990, 14, 626-632.	3.7	133
569	Management of Stage D1 Adenocarcinoma of the Prostate: The Johns Hopkins Experience 1974 to 1987. Journal of Urology, 1990, 144, 1425-1432.	0.4	160
570	The Relationship of Prostate Specific Antigen Levels and Residual Tumor Volume in Stage a Prostate Cancer. Journal of Urology, 1990, 144, 1167-1170.	0.4	41
571	Pathologic findings in clinical stage A2 prostate cancer. Relation of tumor volume, grade, and location to pathologic stage. Cancer, 1990, 65, 1021-1027.	4.1	52
572	Fine-needle core and aspiration biopsy. A new method for diagnosis of prostatic carcinoma. Cancer, 1990, 63, 1846-1855.	4.1	5
573	Advanced small cell carcinoma of the bladder successful treatment with combined radical cystoprostatectomy and adjuvant methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy. Cancer, 1990, 65, 1928-1936.	4.1	79
574	Relationship of severe dysplasia to Stage A (incidental) adenocarcinoma of the prostate. Cancer, 1990, 65, 2321-2327.	4.1	62
575	Relationship of severe dysplasia to Stage B adenocarcinoma of the prostate. Cancer, 1990, 65, 2328-2337.	4.1	70
576	Myxoid malignant fibrous histiocytoma of the bladder. Cancer, 1990, 66, 1836-1842.	4.1	27

#	Article	IF	Citations
577	The significance of low-grade prostate cancer on needle biopsy. A radical prostatectomy study of tumor grade, volume, and stage of the biopsied and multifocal tumor. Cancer, 1990, 66, 1927-1932.	4.1	50
578	Brain biocompatibility of a biodegradable, controlled-release polymer in rats. Journal of Biomedical Materials Research Part B, 1989, 23, 253-266.	3.1	144
579	Lipomeningioma: Report of Three Cases and Review of the Literature. Neurosurgery, 1989, 25, 122-126.	1.1	16
580	Use of Keratin 903 as an Adjunct in the Diagnosis of Prostate Carcinoma. American Journal of Surgical Pathology, 1989, 13, 389-396.	3.7	181
581	Morphometric Measurement of Tumor Volume and Per Cent of Gland Involvement as Predictors of Pathological Stage in Clinical Stage B Prostate Cancer. Journal of Urology, 1989, 141, 341-345.	0.4	168
582	Potency Following Radical Prostatectomy with Wide Unilateral Excision of the Neurovascular Bundle. Journal of Urology, 1987, 138, 823-827.	0.4	189
583	Transitional Cell Carcinoma of the Bladder in an Adolescent with Turner's Syndrome. Journal of Urology, 1987, 137, 398-400.	0.4	7
584	Prostate-specific acid phosphatase immunoreactivity in adenocarcinomas of the urinary bladder. Human Pathology, 1986, 17, 939-942.	2.0	67
585	Frozen Section Detection of Lymph Node Metastases in Prostatic Carcinoma: Accuracy in Grossly Uninvolved Pelvic Lymphadenectomy Specimens. Journal of Urology, 1986, 136, 1234-1237.	0.4	69
586	Prognosis of Untreated Stage A1 Prostatic Carcinoma: A Study of 94 Cases with Extended Followup. Journal of Urology, 1986, 136, 837-839.	0.4	286
587	The Inability of Adrenal Androgens to Stimulate the Adult Human Prostate: An Autopsy Evaluation of Men with Hypogonadotropic Hypogonadism and Panhypopituitarism. Journal of Urology, 1986, 136, 1030-1034.	0.4	58
588	Adenocarcinoma of the prostate with endometrioid features. A light microscopic and immunohistochemical study of ten cases. Cancer, 1986, 57, 111-119.	4.1	143
589	Diffuse leptomeningeal seeding from a malignant spinal cord astrocytoma in a child with neurofibromatosis. Journal of Neuro-Oncology, 1986, 4, 159-163.	2.9	15
590	Mutinous adenocarcinoma of the prostate gland. American Journal of Surgical Pathology, 1985, 9, 299-308.	3.7	138
591	Nuclear roundness factor. A predictor of progression in untreated stage A2 prostate cancer. Cancer, 1984, 54, 1666-1671.	4.1	87
592	Nuclear roundness factor. A predictor of progression in untreated stage A2 prostate cancer. , 1984, 54, 1666.		1